Document:

Exhibit
4.1

 

THIS
WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTION 5.3 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED
UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER,
SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.

 

WARRANT
TO PURCHASE STOCK

 

Company:
Provention Bio, Inc., a Delaware corporation

Warrant
No. 2022-[  ]

Number
of Shares: [  ], subject to adjustment

Type/Series
of Stock: Common Stock, $0.0001 par value per share

Warrant
Price (“Exercise Price”): $6.00 per Share, subject to adjustment

Issue
Date: July [●], 2022

	Expiration
    Date: [●], 2027	See
    also Section 5.1(b).

 

THIS
WARRANT CERTIFIES THAT, for good and valuable consideration, [●] (together with any successor or permitted assignee or transferee
of this warrant to purchase stock (this “Warrant”) or of any shares issued upon exercise hereof, “Holder”)
is entitled to purchase up to the above-stated number of fully paid and non-assessable shares (the “Shares”)
of the above-stated Type/Series of Stock (the “Class”) of the above-named company (the “Company”)
at the above-stated Warrant Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant, subject to the provisions
and upon the terms and conditions set forth in this Warrant.

 

SECTION
1. EXERCISE.

 

1.1
Method of Exercise. Holder may at any time and from time to time exercise this Warrant, in whole or in part, by delivering to
the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as
Appendix 1 and, unless Holder is exercising this Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire
transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for the aggregate
Warrant Price for the Shares being purchased. Notwithstanding any contrary provision herein, if this Warrant was originally executed
and/or delivered electronically, in no event shall Holder be required to surrender or deliver an ink-signed paper copy of this Warrant
in connection with its exercise hereof or of any rights hereunder, nor shall Holder be required to surrender or deliver a paper or other
physical copy of this Warrant in connection with any exercise hereof. The Company shall cause the shares underlying the Warrant (the
“Warrant Shares”) purchased hereunder to be transmitted by the Transfer Agent to the Holder by the date that is the earliest
of (i) two (2) Trading Days after the delivery to the Company of the Notice of Exercise and (ii) the number of Trading Days comprising
the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the “Warrant Share Delivery
Date”). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder
of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant
Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received within the
earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement Period following delivery
of the Notice of Exercise. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to
this section by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise.

 

    	 

     

    

 

“Standard
Settlement Period” means the standard settlement period, expressed in a number of Trading Days, on the Company’s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.

 

“Trading
Day” means a day on which the Common Stock is traded on a Trading Market.

 

1.2
Cashless Exercise. On any exercise of this Warrant, in lieu of payment of the aggregate Warrant Price in the manner as specified
in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the
value of this Warrant, or portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder
such number of fully paid and non-assessable Shares as are computed using the following formula:

 

	 	 	X = Y(A-B)/A
	 	 	 	 
	 	where:	 	 
	 	  	X =	the number of Shares to
    be issued to the Holder;
	 	 	 	 
	 	 	Y = 	the number of Shares with
    respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate
    Warrant Price);
	 	 	 	 
	 	 	A = 	the fair market value (as
    determined pursuant to Section 1.3 below) of one Share; and
	 	 	 	 
	 	 	B =	the Warrant Price.

 

1.3
Fair Market Value. If shares of the Class are then traded or quoted on a nationally recognized securities exchange, inter-dealer
quotation system or over-the-counter market (a “Trading Market”), the fair market value of a Share shall be
the closing price or last sale price of a share of the Class reported for the Business Day immediately before the date on which Holder
delivers this Warrant together with its Notice of Exercise to the Company. If shares of the Class are not then traded in a Trading Market,
the Board of Directors of the Company shall determine the fair market value of a Share in its reasonable good faith judgment.

 

1.4
Delivery of Certificate and New Warrant. Within a reasonable time after Holder exercises this Warrant in the manner set forth
in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise
and, if this Warrant has not been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired.

 

1.5
Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation
of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form,
substance and amount to the Company or, in the case of mutilation, on surrender of this Warrant to the Company for cancellation, the
Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount.

 

    	2

     

    

 

1.6
Treatment of Warrant Upon Acquisition of Company.

 

(a)
Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or series of related
transactions involving: (i) the sale, lease, exclusive license, or other disposition of all or substantially all of the assets of the
Company; (ii) any merger or consolidation of the Company into or with another person or entity (other than a merger or consolidation
effected exclusively to change the Company’s domicile), or any other corporate reorganization, in which the stockholders of the
Company in their capacity as such immediately prior to such merger, consolidation or reorganization, own less than a majority of the
Company’s (or the surviving or successor entity’s) outstanding voting power immediately after such merger, consolidation
or reorganization (or, if such Company stockholders beneficially own a majority of the outstanding voting power of the surviving or successor
entity as of immediately after such merger, consolidation or reorganization, such surviving or successor entity is not the Company);
or (iii) any sale or other transfer by the stockholders of the Company of shares representing at least a majority of the Company’s
then-total outstanding combined voting power.

 

(b)
Treatment of Warrant at Acquisition. In the event of an Acquisition and if Holder has not exercised this Warrant pursuant to Section
1 above as to all Shares, then, following such Acquisition, the Holder shall receive upon exercise hereof the kind and amount of securities,
cash or other property which the Holder would have been entitled to receive (the “Alternate Consideration”) pursuant to such
Acquisition if such exercise had taken place immediately prior to such Acquisition. In any such case, appropriate adjustment (as determined
in good faith by the Board of the Company) shall be made in the application of the provisions set forth herein with respect to the rights
and interests thereafter of the Holder, to the end that the provisions set forth herein (including provisions with respect to changes
in and other adjustments of the Exercise Price) shall thereafter be applicable, as nearly as reasonably may be, in relation to any securities,
cash or other property thereafter deliverable upon the exercise of this Warrant. The Company shall not effect any Acquisition in which
the Company is not the surviving entity or the Alternate Consideration includes securities of another entity unless any successor to
the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver
to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and
the other obligations under this Warrant.

 

    	3

     

    

 

1.7
Limitations on Exercise.

 

Notwithstanding
anything to the contrary herein, the Company shall not effect any exercise of this Warrant, and the holder shall not be entitled to exercise
this Warrant, for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior
to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially owned by the Holder, its Affiliates and
any Persons who are members of a Section 13(d) group with such Holder or its Affiliates to exceed [4.99][19.99]% (the “Maximum
Percentage”) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise,
or (ii) the combined voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other
Persons who are members of a Section 13(d) group with such Holder or its Affiliates to exceed the Maximum Percentage of the combined
voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this paragraph, beneficial
ownership and whether a Holder is a member of a Section 13(d) group shall be calculated and determined in accordance with Section 13(d)
of the Exchange Act and the rules promulgated thereunder. For purposes of this Warrant, in determining the number of outstanding shares
of Common Stock, the Holder may rely on the number of outstanding shares of Common Stock as reflected in (x) the Company’s most
recent Quarterly Report on Form 10-Q or Annual Report on Form 10-K, as the case may be, filed with the Commission prior to the date hereof,
(y) a more recent public announcement by the Company or (z) any other notice by the Company or the Transfer Agent setting forth the number
of shares of Common Stock outstanding. Upon the written request of the Holder, the Company shall within three (3) Trading Days confirm
in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding
shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities of the Company, including
this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice
to the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage specified not in
excess of 19.99% specified in such notice; provided that any such increase will not be effective until the sixty-first (61st) day after
such notice is delivered to the Company. For purposes of this Section 1.7, the aggregate number of shares of Common Stock or voting securities
beneficially owned by the Holder and its Affiliates and any other Persons who are members of a Section 13(d) group with such Holder or
its Affiliates shall include the shares of Common Stock issuable upon: (x) the exercise of this Warrant with respect to which such determination
is being made plus the remaining unexercised and non-cancelled portion of this Warrant but taking into account the limitations on exercise
contained herein, but shall exclude the number of shares of Common Stock which would otherwise be issuable upon exercise of the remaining
unexercised and non-cancelled portion of this Warrant but for the limitations on exercise contained herein; and (y) the exercise or conversion
of the unexercised, non-converted or non-cancelled portion of any other securities of the Company beneficially owned by the Holder or
any of its Affiliates and other Persons who are members of a Section 13(d) group with such Holder or its Affiliates that do not have
voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time
convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), but shall exclude
any such securities subject to any further limitation on conversion or exercise analogous to the limitation contained herein.

 

SECTION
2. ADJUSTMENTS TO THE SHARES AND WARRANT PRICE.

 

2.1
Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on the outstanding shares of the Class
payable in additional shares of the Class or other securities or property (other than cash), then upon exercise of this Warrant, for
each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of securities and property which
Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company
subdivides the outstanding shares of the Class by reclassification or otherwise into a greater number of shares, the number of Shares
purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding
shares of the Class are combined or consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price
shall be proportionately increased and the number of Shares shall be proportionately decreased.

 

    	4

     

    

 

2.2
Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding shares of the Class are
reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series,
then from and after the consummation of such event, this Warrant will be exercisable for the number, class and series of Company securities
that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment
thereafter from time to time in accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply
to successive reclassifications, exchanges, combinations, substitutions, replacements or other similar events.

 

2.3
Adjustment for Cash Distributions.

 

(a)
If the Company, prior to the exercise in whole or expiration of this Warrant, pays a cash distribution to all holders of its Common Stock,
then the number of Warrant Shares issuable upon the exercise of this Warrant shall be adjusted in accordance with the formula:

 

 

where:

 

W’
= the adjusted number of Warrant Shares issuable upon exercise of the Warrant;

W
= the number of Warrant Shares then issuable upon exercise of the Warrant;

M
= the fair market value (as determined pursuant to Section 1.3) per Share on the applicable record date; and

F
= the amount of cash or fair market value on the record date of the evidences of its indebtedness, assets, rights, warrants or other
securities to be distributed in respect of one Share as determined in good faith by the Board of Directors of the Company.

 

(b)
The adjustment pursuant to this Section 2.3 shall be made successively whenever any such distribution is made and shall become effective
immediately after the record date for the determination of holders entitled to receive the distribution.

 

2.4
No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of Shares to be issued
shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company
shall eliminate such fractional Share interest by paying Holder in cash the amount computed by multiplying the fractional interest by
(i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant
Price.

 

2.5
Notice/Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Class and/or number of Shares, the Company, at
the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price,
Class and/or number of Shares and facts upon which such adjustment is based. The Company shall, upon written request from Holder, furnish
Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, Class and
number of Shares in effect upon the date of such adjustment.

 

    	5

     

    

 

SECTION
3. REPRESENTATIONS AND COVENANTS OF THE COMPANY.

 

3.1
Representations and Warranties. The Company represents and warrants to, and agrees with, the Holder as follows:

 

(a)
All Shares which may be issued upon the exercise of this Warrant shall, upon issuance, be duly authorized, validly issued, fully paid
and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable
federal and state securities laws. The Company covenants that it shall at all times cause to be reserved and kept available out of its
authorized and unissued capital stock such number of shares of the Class and other securities as will be sufficient to permit the exercise
in full of this Warrant. The Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may
be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon
which the Common Stock may be listed.

 

3.2
Notice of Certain Events. If the Company proposes at any time to:

 

(a)
declare any dividend or distribution upon the outstanding shares of the Class, whether in cash, property, stock, or other securities
and whether or not a regular cash dividend;

 

(b)
offer for subscription or sale pro rata to the holders of the outstanding shares of the Class any additional shares of any class or series
of the Company’s stock (other than pursuant to contractual pre-emptive rights);

 

(c)
effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the outstanding shares of the
Class; or

 

(d)
effect an Acquisition or to liquidate, dissolve or wind up;

 

then,
in connection with each such event, the Company shall give Holder notice thereof at the same time and in the same manner as it gives
notice thereof to holders of the outstanding shares of the Class.

 

The
Company will also provide information requested by Holder from time to time, within a reasonable time following each such request, that
is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements.

 

SECTION
4. REPRESENTATIONS, WARRANTIES OF THE HOLDER.

 

The
Holder represents and warrants to the Company as follows:

 

4.1
Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder are being acquired
for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within
the meaning of the Act. Holder also represents that it has not been formed for the specific purpose of acquiring this Warrant or the
Shares.

 

4.2
Disclosure of Information. Holder is aware of the Company’s business affairs and financial condition and has received or
has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect
to the acquisition of this Warrant and its underlying securities. Holder further has had an opportunity to ask questions and receive
answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain
additional information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense)
necessary to verify any information furnished to Holder or to which Holder has access.

 

    	6

     

    

 

4.3
Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities involves substantial
risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear
the economic risk of such Holder’s investment in this Warrant and its underlying securities and has such knowledge and experience
in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its
underlying securities and/or has a preexisting personal or business relationship with the Company and certain of its officers, directors
or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances
of such persons.

 

4.4
Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D promulgated under
the Act.

 

4.5
The Act. Holder understands that this Warrant and the Shares issuable upon exercise hereof have not been registered under the
Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s
investment intent as expressed herein. Holder understands that this Warrant and the Shares issued upon any exercise hereof must be held
indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from
such registration and qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act.

 

4.6
No Voting Rights. Holder, as a Holder of this Warrant, will not have any voting rights until the exercise of this Warrant.

 

SECTION
5. MISCELLANEOUS.

 

5.1
Term; Automatic Cashless Exercise Upon Expiration.

 

(a)
Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at any time and from time
to time on or before 6:00 PM, Eastern time, on the Expiration Date and shall be void thereafter.

 

(b) Automatic Cashless
Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market value of one Share as determined in accordance
with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and
as of such date to be exercised pursuant to Section 1.2 above as to all Shares for which it shall not previously have been exercised,
and the Company shall, within a reasonable time, deliver a certificate representing the Shares issued upon such exercise to Holder.

 

5.2
Legends. Each certificate evidencing Shares shall be imprinted with a legend in substantially the following form:

 

THE
SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”),
OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN
WARRANT TO PURCHASE STOCK ISSUED BY THE ISSUER TO [●] DATED JULY [●],
2022 MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL
REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL IN FORM
AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER
IS EXEMPT FROM SUCH REGISTRATION.

 

    	7

     

    

 

5.3
Compliance with Securities Laws on Transfer. This Warrant and the Shares issued upon exercise of this Warrant may not be transferred
or assigned in whole or in part except in compliance with applicable federal
and state securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation
letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). The Company shall not require
Holder to provide an opinion of counsel if the transfer is to an affiliate of Holder, provided that any such transferee is an “accredited
investor” as defined in Regulation D promulgated under the Act.

 

5.4
Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall be deemed delivered
and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered
or certified mail, postage prepaid, (iii) upon actual receipt if given by facsimile or electronic mail and such receipt is confirmed
in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee
prepaid, in any case at such address as may have been furnished to the Company or Holder, as the case may be, in writing by the Company
or such Holder from time to time in accordance with the provisions of this Section 5.4. All notices to Holder shall be addressed as follows
until the Company receives notice of a change of address in connection with a transfer or otherwise:

 

[●]

Attn:
[____]

[Address]

Telephone:
[____]

Email
address: [____]

 

Notice
to the Company shall be addressed as follows until Holder receives notice of a change in address:

 

Provention
Bio, Inc.

Attn:
Chief Financial Officer

55
Broad Street, 2nd Floor

Red
Bank, NJ 07701

Telephone:
(908) 336-0360

Email:
tchauche@proventionbio.com

 

With
a copy (which shall not constitute notice) to:

 

Ropes
& Gray LLP

Attn:
Thomas J. Danielski

Prudential
Tower

800
Boylston Street

Boston,
MA 02199

Telephone:
(617) 951-7000

Email:
thomas.danielski@ropesgray.com

 

    	8

     

    

 

5.5
Amendment and Waiver. This Warrant and any term hereof may be amended or otherwise changed, waived, discharged or terminated (either
generally or in a particular instance and either retroactively or prospectively) only by an instrument in writing signed by the party
against which enforcement of such amendment or other change, waiver, discharge or termination is sought.

 

5.6
Attorneys’ Fees. In the event of any dispute between the parties concerning the terms and provisions of this Warrant, the
party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable
attorneys’ fees.

 

5.7
Counterparts; Facsimile/Electronic Signatures. This Warrant may be executed by one or more of the parties hereto in any number
of separate counterparts, all of which together shall constitute one and the same instrument. The Company, Holder and any other party
hereto may execute this Warrant by electronic means and each party hereto recognizes and accepts the use of electronic signatures and
the keeping of records in electronic form by any other party hereto in connection with the execution and storage hereof. To the extent
that this Warrant or any agreement subject to the terms hereof or any amendment hereto is executed, recorded or delivered electronically,
it shall be binding to the same extent as though it had been executed on paper with an original ink signature, as provided under applicable
law, including, without limitation, any state law based on the Uniform Electronic Transactions Act. The fact that this Warrant is executed,
signed, stored or delivered electronically shall not prevent the transfer by any Holder of this Warrant pursuant to, or the enforcement
of, the terms hereof.

 

5.8
Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise affect the meaning
of any provision of this Warrant.

 

5.9
Business Days. “Business Day” is any day that is not a Saturday, Sunday or a day on which The Nasdaq
Global Select Market and commercial banks in the City of New York are closed.

 

SECTION
6. GOVERNING LAW, VENUE, JURY TRIAL WAIVER, AND JUDICIAL REFERENCE.

 

6.1
Governing Law. This Warrant shall be governed by and construed in accordance with the laws of the State of New York, without giving
effect to its principles regarding conflicts of law.

 

6.2
Jurisdiction and Venue. The Company and Holder each submit to the exclusive jurisdiction of the state and federal courts in the
State of New York; provided, however, that nothing in this Warrant shall be deemed to operate to preclude Holder from bringing suit or
taking other legal action in any other jurisdiction to enforce a judgment or other court order in favor of Holder. The Company expressly
submits and consents in advance to such jurisdiction in any action or suit commenced in any such court, and the Company hereby waives
any objection that it may have based upon lack of personal jurisdiction, improper venue, or forum non conveniens and hereby consents
to the granting of such legal or equitable relief as is deemed appropriate by such court. The Company hereby waives personal service
of the summons, complaints, and other process issued in such action or suit and agrees that service of such summons, complaints, and
other process may be made in accordance with Section 5.4 of this Warrant.

 

6.3
Jury Trial Waiver. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE COMPANY AND HOLDER EACH WAIVE THEIR RIGHT TO A JURY
TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS WARRANT, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER
CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR THE PARTIES’ AGREEMENT TO THIS WARRANT. EACH PARTY HAS REVIEWED THIS WAIVER WITH
ITS COUNSEL.

 

6.4
Survival. This Section 6 shall survive the termination of this Warrant.

 

[Remainder
of page left blank intentionally]

 

[Signature
page follows]

 

    	9

     

    

 

IN
WITNESS WHEREOF, the parties have caused this Warrant to Purchase Stock to be executed by their duly authorized representatives effective
as of the Issue Date written above.

 

	“COMPANY”	 
	 	 
	PROVENTION BIO, INC.	 
	 	 	 
	By: 	 	 
	Name: 	Thierry Chauche	 
	Title: 	Chief Financial Officer	 
	 	 	 
	“HOLDER”	 
	 	 	 
	[●]	 	 
	 	 	 
	By:	 	 
	Name:	 	 
	Title: 	 	 

 

    	10

     

    

 

APPENDIX
1

 

NOTICE
OF EXERCISE

 

1.
The undersigned Holder hereby exercises its right to purchase ___________ shares of the Common Stock of __________________ (the “Company”)
in accordance with the attached Warrant To Purchase Stock, and tenders payment of the aggregate Warrant Price for such shares as follows:

 

	 	[  ] 	check in the amount of $________
    payable to order of the Company enclosed herewith
	 	 	 
	 	[  ]	Wire transfer of immediately available funds to the
    Company’s account
	 	 	 
	 	[  ]	Cashless Exercise pursuant to Section 1.2 of the Warrant
	 	 	 
	 	[  ]	Other [Describe] __________________________________________

 

2.
Please issue a certificate or certificates representing the Shares in the name specified below:

 

	 	 	 
	 	Holder’s
Name	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Address)	 

 

3.
By its execution below and for the benefit of the Company, Holder hereby restates each of the representations and warranties in Section
4 of the Warrant to Purchase Stock as of the date hereof.

 

	 	HOLDER:
	 	 
	 	 
	 	 	       
	 	By:	 
	 	Name:	
	 	Title:	 
	 	(Date):	 

 

    	Schedule 1Exhibit
10.1

 

SECURITIES
PURCHASE AGREEMENT

 

This
Securities Purchase Agreement (this “Agreement”) is dated as of July 7, 2022 (the “Effective Date”),
among Provention Bio, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature
pages hereto (each a “Purchaser” and collectively the “Purchasers”).

 

WHEREAS,
the Company and the Purchasers are executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”).

 

WHEREAS,
each Purchaser wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated in this Agreement, (i)
the number of shares of common stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth
opposite such Purchaser’s name on Exhibit A hereto, which aggregate number of shares of Common Stock for all Purchasers
together shall be [  ] shares of Common Stock (the “Shares”) and (ii) a warrant to acquire up to that number
of additional Shares set forth opposite such Purchaser’s name on Exhibit A (the “Warrants”), in
substantially the form attached hereto as Exhibit B (as exercised, the “Warrant Shares”). The Shares,
the Warrants and the Warrant Shares collectively are referred to herein as the “Securities”.

 

WHEREAS,
in connection with the offering and sale of the Securities, the Company has entered into an engagement letter dated June 11, 2022 (the
“Engagement Letter”), with Jefferies LLC (the “Placement Agent”).

 

Now,
Therefore, in consideration of the mutual covenants
contained in this Agreement, and for other good and valuable consideration the receipt and adequacy of which are hereby acknowledged,
the Company and each Purchaser, severally and not jointly, agree as follows:

 

1.
DEFINITIONS

 

1.1
Definitions. In addition to the terms defined elsewhere in this Agreement, the following terms have the meanings set forth in this
Section 1.1:

 

“Closing”
means the closing of the purchase and sale of the Securities on the Closing Date pursuant to Section 2.1 of this Agreement.

 

“Closing
Date” means July 13, 2022.

 

“Closing
Price” means $[  ] per share.

 

“Commission”
means the United States Securities and Exchange Commission.

 

    	1

     

    

 

“Common
Stock” means the common stock of the Company, $0.0001 par value per share, and any other class of securities into which
such securities may hereafter be reclassified or changed into.

 

“Effectiveness
Deadline” means, with respect to the Mandatory Registration Statement, the sixtieth (60th) calendar day following the Closing
Date (or, in the event the SEC reviews and has written comments to the Mandatory Registration Statement, the ninetieth (90th) calendar
day following the Closing Date); provided, however, that if the Company is notified by the Commission that the Mandatory Registration
Statement will not be reviewed or is no longer subject to further review and comments, the Effectiveness Deadline as to such Registration
Statement shall be the fifth (5th) business day following the date on which the Company is so notified if such date precedes the dates
otherwise required above; provided, further, that if the Effectiveness Deadline falls on a Saturday, Sunday or other day that the Commission
is closed for business, the Effectiveness Deadline shall be extended to the next business day on which the Commission is open for business.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.

 

“GAAP”
means U.S. generally accepted accounting principles consistently applied.

 

“Investment
Company Act” means the Investment Company Act of 1940, as amended.

 

“Material
Adverse Effect” means material adverse change in the condition, financial or otherwise, or in the earnings, business affairs
or business prospects of the Company, whether or not arising in the ordinary course of business.

 

“Nasdaq”
means The Nasdaq Global Select Market.

 

“Rule
144” means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended from time
to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such Rule.

 

“SEC
Reports” means collectively all reports, schedules, forms, statements and other documents required to be filed by the Company
under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, since February 25, 2021 (including the exhibits thereto
and documents incorporated by reference therein).

 

“Short
Sales” means all “short sales” as defined in Rule 200 of Regulation SHO of the Exchange Act, but shall be deemed
to not include the location and/or reservation of borrowable shares of Common Stock.

 

“Trading
Day” means a day on which the Common Stock is traded on Nasdaq.

 

“Transaction
Documents” means this Agreement, the Warrants and any other documents or agreements executed and delivered to the Purchasers
in connection with the transactions contemplated hereunder.

 

    	2

     

    

 

2.
PURCHASE AND SALE

 

2.1
Closing.

 

(a)
At the Closing, upon the terms set forth herein, the Company hereby agrees to issue and sell to each Purchaser, and each Purchaser agrees
to purchase from the Company, severally and not jointly, the number of Shares set forth opposite such Purchaser’s name on Exhibit
A hereto, at a purchase price equal to the Closing Price per share of Common Stock.

 

(b)
At the Closing, upon the terms set forth herein, the Company hereby agrees to issue and sell to each Purchaser, and each Purchaser agrees
to purchase from the Company, severally and not jointly, a Warrant exercisable for a number of Warrant Shares set forth opposite such
Purchaser’s name on Exhibit A hereto, at a purchase price equal to $[  ] per Warrant Share.

 

(c)
At the Closing, each Purchaser shall deliver to the Company via wire transfer immediately available funds equal to the purchase price
set forth opposite such Purchaser’s name on Exhibit A hereto and the Company shall deliver to each Purchaser its respective
Securities in the amount set forth opposite such Purchaser’s name on Exhibit A hereto, deliverable at the Closing on the Closing
Date, in accordance with Section 2.2 of this Agreement. The Closing shall occur at 10:00 a.m. (New York City time) on the Closing
Date or such other time and location as the parties shall mutually agree.

 

2.2
Deliveries; Closing Conditions.

 

(a)
At the Closing, the Company will deliver or cause to be delivered to each Purchaser certificate(s) or book-entry shares representing
the Common Stock, purchased by such Purchaser, registered in such Purchaser’s name. Such delivery shall be against payment of the
purchase price therefor by such Purchaser by wire transfer of immediately available funds to the Company in accordance with the Company’s
written wiring instructions.

 

(b)
At the Closing, the Company will deliver or cause to be delivered to each Purchaser the Warrant purchased by such Purchaser registered
in the Purchaser’s name. Such delivery shall be against payment of the purchase price therefor by the Purchaser by wire transfer
of immediately available funds to the Company in accordance with the Company’s written wiring instructions.

 

(c)
The respective obligations of the Company, on the one hand, and each Purchaser, on the other hand, hereunder in connection with the Closing
are subject to the following conditions being met:

 

(i)
the accuracy in all material respects on the Closing Date of the representations and warranties contained herein (unless made as of a
specified date therein) of the Company (with respect to the obligations of the Purchasers) and the Purchasers (with respect to the obligations
of the Company);

 

    	3

     

    

 

(ii)
all obligations, covenants and agreements of the Company (with respect to the obligations of the Purchasers) and the Purchasers (with
respect to the obligations of the Company) required to be performed at or prior to the Closing Date shall have been performed in all
material respects;

 

(iii)
The Purchasers shall have received a certificate of the Secretary of the Company, dated as of the Closing Date in form and substance
reasonably satisfactory to the Purchasers;

 

(iv)
The Purchasers shall have received a certificate signed by the Chief Executive Officer of the Company, dated as of the Closing Date in
form and substance reasonably satisfactory to the Purchasers;

 

(v)
The Purchasers shall have received an opinion of Ropes & Gray LLP, counsel for the Company, dated as of the Closing Date, in a form
reasonably satisfactory to the Purchasers; and

 

(vi)
No Material Adverse Effect has occurred.

 

3.
REPRESENTATIONS AND
WARRANTIES

 

3.1
Representations and Warranties of the Company. Assuming the accuracy of the representations and warranties of the Purchasers set
forth in Section 3.2 of this Agreement and except as set forth in the SEC Reports, which disclosures serve to qualify these representations
and warranties in their entirety, the Company represents and warrants to the Purchasers and the Placement Agent that the statements contained
in this Section 3.1 are true and correct as of the date hereof and as of the Closing Date:

 

(a)
The Company was not and is not an Ineligible Issuer (as defined in Rule 405 under the Securities Act), without taking account of any
determination by the Commission pursuant to Rule 405 that it is not necessary that the Company be considered an Ineligible Issuer.

 

(b)
The Company has been duly organized and is validly existing as a corporation in good standing under the laws of the State of Delaware
and has corporate power and authority to own, lease and operate its properties and to conduct its business as described in the SEC Reports
and to enter into and perform its obligations under this Agreement and the Warrants; and the Company is duly qualified as a foreign corporation
to transact business and is in good standing in each other jurisdiction in which such qualification is required, whether by reason of
the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or to be in good standing
would not result in a Material Adverse Effect.

 

(c)
The Company has no subsidiaries (as defined in Rule 405 under the Securities Act).

 

(d)
The Shares to be purchased by the Purchasers from the Company have been duly authorized for issuance and sale to the Purchasers pursuant
to this Agreement and, when issued and delivered by the Company pursuant to this Agreement against payment of the consideration set forth
herein, will be validly issued and fully paid and non-assessable; and the issuance of the Shares is not subject to the preemptive or
other similar rights of any securityholder of the Company.

 

    	4

     

    

 

(e)
The Warrants have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and binding agreements
of the Company, enforceable against the Company in accordance with their terms, except as the enforcement thereof may be limited by bankruptcy,
insolvency, reorganization, moratorium or other similar laws relating to or affecting the rights and remedies of creditors or by general
equitable principles; the Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the Warrants; the
Warrant Shares, when issued and delivered upon exercise of the Warrants in accordance therewith, will be validly issued, fully paid and
nonassessable, and the issuance of the Warrant Shares not subject to the preemptive or other similar rights of any securityholder of
the Company.

 

(f)
The authorized capital stock of the Company consists of 150,000,000 shares of Common Stock and 25,000,000 shares of undesignated preferred
stock. As of May 2, 2022, there were no shares of preferred stock issued and outstanding and there were 64,040,216 shares of Common Stock
issued and outstanding, of which no shares were owned by the Company. There are no other shares of any other class or series of capital
stock of the Company issued or outstanding.

 

(g)
This Agreement has been duly authorized, executed and delivered by the Company.

 

(h)
The Company is not (A) in violation of its charter, by-laws or similar organizational document, (B) in default in the performance or
observance of any obligation, agreement, covenant or condition contained in any contract, indenture, mortgage, deed of trust, loan or
credit agreement, note, lease or other agreement or instrument to which the Company is a party or by which it may be bound or to which
any of the properties or assets of the Company is subject (collectively, “Agreements and Instruments”), except
for such defaults that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) in violation of any law, statute,
rule, regulation, judgment, order, writ or decree of any arbitrator, court, governmental body, regulatory body, administrative agency
or other authority, body or agency having jurisdiction over the Company or any of its properties, assets or operations (each, a “Governmental
Entity”), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect. The
execution, delivery and performance of this Agreement, and the consummation of the transactions contemplated herein and compliance by
the Company with its obligations hereunder, have been duly authorized by all necessary corporate action and do not and will not, whether
with or without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event
(as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties or assets of
the Company pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens,
charges or encumbrances that would not, singly or in the aggregate, result in a Material Adverse Effect), nor will such action result
in any violation of the provisions of the charter, by-laws or similar organizational document of the Company or any law, statute, rule,
regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a “Repayment Event” means any event
or condition which gives the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s
behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company.

 

    	5

     

    

 

(i)
The Company is not, and after giving effect to the offering and sale of the Securities and the application of the proceeds thereof as
described in Section 5.4 of this Agreement, will not be, an “investment company” or an entity “controlled”
by an “investment company,” as such terms are defined in the Investment Company Act.

 

(j)
There are no persons with registration rights or other similar rights to have any securities registered for sale pursuant to the Resale
Registration Statement (as defined in Section 4.1(a) hereof) or otherwise registered for sale or sold by the Company under the Securities
Act pursuant to this Agreement, except any such right that has been validly waived in writing as of the date of this Agreement.

 

(k)
The Company possesses such permits, licenses, approvals, consents and other authorizations (collectively, “Governmental Licenses”)
issued by the appropriate Governmental Entities necessary to conduct the business now operated by the Company (including, without limitation,
all such permits, licenses, approvals, consents and other authorizations required by the U.S. Food and Drug Administration (the “FDA”),
the European Medicines Agency (the “EMA”), or any other federal, state, local or foreign agencies or bodies
engaged in the regulation of clinical or preclinical studies, pharmaceuticals, biologics, biohazardous substances or activities related
to the business now operated by the Company), except where the failure so to possess would not, singly or in the aggregate, result in
a Material Adverse Effect. The Company is in compliance with the terms and conditions of all Governmental Licenses, except where the
failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. The Company has fulfilled and performed
all of its material obligations with respect to the Governmental Licenses and, to the knowledge of the Company, no event has occurred
which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment
of the rights of the Company as a holder of any permit, except where the failure to so fulfill or perform, or the occurrence of such
event, would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in
full force and effect, except where the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in
full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. The Company has not received any notice
of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject
of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.

 

(l)
No consent, approval, authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory
authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Securities
and the consummation of the transactions contemplated by this Agreement, other than (i) any necessary qualification under the securities
or blue sky laws of the various jurisdictions in which the Securities are being offered, (ii) any listing applications and related consents
or any notices required by Nasdaq in the ordinary course of the offering of the Securities, (iii) filings with the Commission under the
Securities Act contemplated by this Agreement or (iv) filings with the Commission on Form 8-K with respect to this Agreement.

 

    	6

     

    

 

(m)
The Company’s Common Stock is registered under Section 12 of the Exchange Act. The Company has filed all SEC Reports on a timely
basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of any such
extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Exchange Act
and, in each case, to the rules promulgated thereunder, as applicable, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading.

 

(n)
The financial statements included or incorporated by reference in the SEC Reports, together with the related schedules and notes, comply
as to form in all material respects with Regulation S-X of the Securities Act, and present fairly, in all material respects, the financial
position of the Company at the dates indicated and the statement of operations, stockholders’ equity and cash flows of the Company
for the periods specified; said financial statements have been prepared in conformity with GAAP, except, in the case of unaudited interim
financial statements, subject to normal year-end adjustments. The supporting schedules, if any, present fairly, in all material respects,
in accordance with GAAP the information required to be stated therein. The interactive data in eXtensible Business Reporting Language
included or incorporated by reference in the SEC Reports fairly presents the information called for in all material respects and has
been prepared in accordance with the Commission’s rules and guidelines applicable thereto.

 

(o)
Except as disclosed in the SEC Reports, there is no action, suit, proceeding, inquiry or investigation before or brought by any Governmental
Entity (including, without limitation, any action, suit proceeding, inquiry or investigation before or brought by the FDA or EMA) now
pending or, to the knowledge of the Company, threatened, against or affecting the Company, which would reasonably be expected to result
in a Material Adverse Effect, or which would reasonably be expected to materially and adversely affect their respective properties or
assets or the consummation of the transactions contemplated in this Agreement or the performance by the Company of its obligations hereunder;
and the aggregate of all pending legal or governmental proceedings to which the Company is a party or of which any of their respective
properties or assets is the subject which are not described in the SEC Reports, including ordinary routine litigation incidental to the
business, would not result in a Material Adverse Effect.

 

(p)
The Company is in compliance with all provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder
(collectively, the “Sarbanes-Oxley Act”) which the Company is required to comply with, and is actively taking
steps to ensure that it will be in compliance with other provisions of the Sarbanes-Oxley Act that will become applicable to the Company
at all times after the effectiveness of its existing shelf registration statement on Form S-3 and the Resale Registration Statement (taking
into account all exemptions and phase-in periods provided under the Jumpstart Our Business Startups Act and otherwise under applicable
law).

 

(q)
EisnerAmper LLP, who have certified certain financial statements of the Company, is an independent registered public accounting firm
with respect to the Company within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight
Board (United States) and as required by the Securities Act and the Exchange Act.

 

    	7

     

    

 

(r)
Prior to the date of this Agreement, (A) there has been no Material Adverse Effect, (B) except as described in the SEC Reports, there
have been no transactions entered into by the Company, other than those in the ordinary course of business, which are material with respect
to the Company, (C) except as described in the SEC Reports, there have been no material liabilities or obligations, direct or contingent,
entered into by the Company and (D) there has been no dividend or distribution of any kind declared, paid or made by the Company on any
class of its capital stock.

 

(s)
The Company has good and marketable title to all real property owned by it and good title to all other properties owned by it, in each
case, free and clear of all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind except such
as (A) are described in the SEC Reports or (B) do not, singly or in the aggregate, materially affect the value of such property and do
not materially interfere with the use made and proposed to be made of such property by the Company; and all of the leases and subleases
material to the business of the Company, considered as one enterprise, and under which the Company holds properties described in the
SEC Reports, are in full force and effect, and the Company has not received any notice of any material claim of any sort that has been
asserted by anyone adverse to the rights of the Company under any of the leases or subleases mentioned above, or affecting or questioning
the rights of the Company to the continued possession of the leased or subleased premises under any such lease or sublease.

 

(t)
Except as described in the SEC Reports, to the knowledge of the Company, the Company owns or has valid, binding and enforceable licenses
or other rights under the patents, patent applications, licenses, inventions, copyrights, know how (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures), trademarks, service marks, trade names
or other intellectual property necessary for, or used in the conduct, or the proposed conduct, of the business of the Company in the
manner described in the SEC Reports (collectively, the “Intellectual Property”); to the knowledge of the Company,
the patents, trademarks, and copyrights, if any, included within the Intellectual Property are valid, enforceable, and subsisting; other
than as disclosed in the SEC Reports, (A) the Company is not obligated to pay a material royalty, grant a license to, or provide other
material consideration to any third party in connection with the Intellectual Property, (B) the Company has not received any notice of
any claim of infringement, misappropriation or conflict with any asserted rights of others with respect to any of the Company’s
drug candidates, services, processes or Intellectual Property, (C) to the knowledge of the Company, neither the sale nor use of any of
the discoveries, inventions, drug candidates, services or processes of the Company referred to in the SEC Reports do or will, to the
knowledge of the Company, infringe, misappropriate or violate any right or valid patent claim of any third party, (D) none of the technology
employed by the Company has been obtained or is being used by the Company in material violation of any contractual obligation binding
on the Company or, to the Company’s knowledge, upon any of its officers, directors or employees or otherwise in violation of the
rights of any persons, (E) to the knowledge of the Company, no third party has any ownership right in or to any Intellectual Property
that is owned by the Company, other than any co-owner of any patent constituting Intellectual Property who is listed on the records of
the U.S. Patent and Trademark Office (the “USPTO”) and any co-owner of any patent application constituting
Intellectual Property who is named in such patent application, and, to the knowledge of the Company, no third party has any ownership
right in or to any Intellectual Property in any field of use that is exclusively licensed to the Company, other than any licensor to
the Company of such Intellectual Property, (F) there is no material infringement by third parties of any Intellectual Property, (G) there
is no pending or, to the Company’s knowledge, threatened action, suit, proceeding, or claim by others challenging the Company’s
rights in or to any Intellectual Property, and (H) there is no pending or, to the Company’s knowledge, threatened action, suit,
proceeding or claim by others challenging the validity or scope of any Intellectual Property. The Company is in compliance in all material
respects with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company, and all such agreements
are in full force and effect.

 

    	8

     

    

 

(u)
All patents and patent applications owned by or licensed to the Company or under which the Company has rights have, to the knowledge
of the Company, been duly and properly filed and maintained; to the knowledge of the Company, the parties prosecuting such patent applications
have complied with their duty of candor and disclosure to the USPTO in connection with such applications; and the Company is not aware
of any facts required to be disclosed to the USPTO that were not disclosed to the USPTO and which would preclude the grant of a patent
in connection with any such application or would reasonably be expected to form the basis of a finding of invalidity with respect to
any patents that have issued with respect to such applications. To the Company’s knowledge, all patents and patent applications
owned by the Company and filed with the USPTO or any foreign or international patent authority (the “Company Patent Rights”)
and all patents and patent applications in-licensed by the Company and filed with the USPTO or any foreign or international patent authority
(the “In-licensed Patent Rights”) have been duly and properly filed; the Company believes it has complied with
its duty of candor and disclosure to the USPTO for the Company Patent Rights and, to the Company’s knowledge, the licensors of
the In-licensed Patent Rights have complied with their duty of candor and disclosure to the USPTO for the In-licensed Patent Rights.

 

(v)
No labor dispute with the employees of the Company exists or, to the knowledge of the Company, is imminent, and the Company is not aware
of any existing or imminent labor disturbance by the employees of any of its principal suppliers, manufacturers, customers or contractors,
which, in either case, would result in a Material Adverse Effect.

 

(w)
Except as described in the SEC Reports or would not, singly or in the aggregate, result in a Material Adverse Effect, (A) the Company
is not in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common
law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment,
relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water, groundwater,
land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened
release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products, asbestos-containing
materials or mold (collectively, “Hazardous Materials”) or to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”),
(B) the Company all permits, authorizations and approvals required under any applicable Environmental Laws and is in compliance with
their requirements, (C) there are no pending or, to the knowledge of the Company threatened, administrative, regulatory or judicial actions,
suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental
Law against the Company and (D) there are no events or circumstances that would reasonably be expected to form the basis of an order
for clean-up or remediation, or an action, suit or proceeding by any private party or Governmental Entity, against or affecting the Company
relating to Hazardous Materials or any Environmental Laws.

 

    	9

     

    

 

(x)
The Company carries or is entitled to the benefits of insurance, with financially sound and reputable insurers, in such amounts and covering
such risks as is generally maintained by companies in the same or similar business, and all such insurance is in full force and effect.
The Company has no reason to believe that it will not be able (A) to renew its existing insurance coverage as and when such policies
expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business as now
conducted and at a cost that would not result in a Material Adverse Effect. The Company has not been denied any insurance coverage which
it has sought or for which it has applied.

 

(y)
The Company (i) does not have any material lending or other relationship with any bank or lending affiliate of the Placement Agent and
(ii) does not intend to use any of the proceeds from the sale of the Securities hereunder to repay any outstanding debt owed to any affiliate
of the Placement Agent.

 

(z)
The Company maintains effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15 under the Exchange
Act) and a system of internal accounting controls sufficient to provide reasonable assurances that (A) transactions are executed in accordance
with management’s general or specific authorization; (B) transactions are recorded as necessary to permit preparation of financial
statements in conformity with GAAP and to maintain accountability for assets; (C) access to assets is permitted only in accordance with
management’s general or specific authorization; (D) the recorded accountability for assets is compared with the existing assets
at reasonable intervals and appropriate action is taken with respect to any differences; and (E) the interactive data in eXtensible Business
Reporting Language included or incorporated by reference in the SEC Reports fairly presents the information called for in all material
respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. Except as described in the
SEC Reports, since the end of the Company’s most recent audited fiscal year, there has been (1) no material weakness in the Company’s
internal control over financial reporting (whether or not remediated) and (2) no change in the Company’s internal control over
financial reporting that has materially adversely affected, or is reasonably likely to materially adversely affect, the Company’s
internal control over financial reporting.

 

(aa)
The Company has no debt securities or preferred stock that is rated by any “nationally recognized statistical rating organization”
(as that term is defined by the Commission for purposes of Rule 436(g)(2) under the Securities Act).

 

    	10

     

    

 

(bb)
The Company has operated its business in a manner compliant in all material respects with all United States federal, state, local and
non-United States privacy, data security and data protection laws and regulations applicable to the Company’s collection, use,
transfer, protection, disposal, disclosure, handling, storage and analysis of personal data. The Company has been and is in compliance
in all material respects with internal policies and procedures designed to ensure the integrity and security of the data collected, handled
or stored in connection with its business; the Company has been and is in compliance in all material respects with internal policies
and procedures designed to ensure compliance with the health care laws that govern privacy and data security and take, and has taken
reasonably appropriate steps designed to assure compliance with such policies and procedures. The Company has taken reasonable steps
to maintain the confidentiality of its personally identifiable information, protected health information, consumer information and other
confidential information of the Company and any third parties in its possession (“Sensitive Company Data”).
The tangible or digital information technology systems (including computers, screens, servers, workstations, routers, hubs, switches,
networks, data communications lines, technical data and hardware), software and telecommunications systems used or held for use by the
Company (the “Company IT Assets”) are adequate and operational for, in accordance with their documentation
and functional specifications, the business of the Company as now operated and as currently proposed to be conducted as described in
the SEC Reports. The Company has used reasonable efforts to establish, and has established, commercially reasonable disaster recovery
and security plans, procedures and facilities for the business consistent with industry standards and practices in all material respects,
including, without limitation, for the Company IT Assets and data held or used by or for the Company. To the Company’s knowledge,
the Company has not suffered or incurred any security breaches, compromises or incidents with respect to any Company IT Asset or Sensitive
Company Data, except where such breaches, compromises or incidents would not reasonably be expected to, singly or in the aggregate, result
in a Material Adverse Effect; and there has been no unauthorized or illegal use of or access to any Company IT Asset or Sensitive Company
Data by any unauthorized third party. The Company has not been required to notify any individual of any information security breach,
compromise or incident involving Sensitive Company Data.

 

(cc)
All statistical or market-related data included in the SEC Reports are based on or derived from sources that the Company reasonably believes
to be reliable and accurate, and the Company has obtained the written consent to the use of such data from such sources to the extent
required.

 

(dd)
Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any
action which is designed, or would be expected, to cause or result in, or which constitutes, the stabilization or manipulation of the
price of any security of the Company to facilitate the sale or resale of the Securities or to result in a violation of Regulation M under
the Exchange Act (it being understood that the Company makes no representation with respect to any action taken by any Purchaser or their
affiliates).

 

(ee)
None of the Company or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on
behalf of the Company is aware of or has taken any action, directly or indirectly, that would result in a violation by such persons of
the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (the “FCPA”),
including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance
of an offer, payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization
of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any foreign political
party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company has and, to the
knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA and have instituted and maintain
policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith.

 

    	11

     

    

 

(ff)
The operations of the Company are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting
requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering
statutes of all jurisdictions where the Company conducts business, the rules and regulations thereunder and any related or similar rules,
regulations or guidelines issued, administered or enforced by any governmental agency (collectively, the “Anti-Money Laundering
Laws”) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator
involving the Company with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened.

 

(gg)
None of the Company, or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or representative of the
Company is an individual or entity (“Person”) currently the subject or target of any sanctions administered
or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign
Assets Control, the United Nations Security Council, the European Union, Her Majesty’s Treasury, or other relevant sanctions authority
(collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that
is the subject of Sanctions; and the Company will not directly or indirectly use the proceeds of the sale of the Securities, or lend,
contribute or otherwise make available such proceeds to joint venture partners or other Person, to fund any activities of or business
with any Person, or in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner
that will result in a violation by any Person (including any Person participating in the transaction, whether as underwriter, advisor,
investor or otherwise) of Sanctions.

 

(hh)
Except as described in the SEC Reports, the Company: (A) is and at all times has been in material compliance with all statutes, rules
or regulations of the FDA and other comparable Governmental Entities applicable to the ownership, testing, development, manufacture,
packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of
any product under development, manufactured or distributed by the Company (“Applicable Laws”); (B) has not
received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or written notice from
the FDA or any Governmental Authority alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates,
approvals, clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws
(“Authorizations”); (C) possesses all material Authorizations and such Authorizations are valid and in full
force and effect and the Company is not in material violation of any term of any such Authorizations; (D) has not received notice of
any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any Governmental
Authority or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations
and has no knowledge that the FDA or any Governmental Authority or third party is considering any such claim, litigation, arbitration,
suit, investigation or proceeding; (E) has not received notice that the FDA or any Governmental Authority has taken, is taking or intends
to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any Governmental
Authority is considering such action; and (F) has filed, obtained, maintained or submitted all material reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that
all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially
complete and correct on the date filed (or were corrected or supplemented by a subsequent submission).

 

    	12

     

    

 

(ii)
The Company has operated and currently is in compliance with all applicable health care laws, rules and regulations (except where such
failure to operate or non-compliance would not, singly or in the aggregate, result in a Material Adverse Effect), including, without
limitation, (i) the Federal, Food, Drug and Cosmetic Act (21 U.S.C. §§ 301 et seq.); (ii) all applicable federal, state, local
and all applicable foreign healthcare related fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute
(42 U.S.C. § 1320a-7b(b)), the U.S. Physician Payments Sunshine Act (42 U.S.C. § 1320a-7h), the civil False Claims Act (31
U.S.C. §§ 3729 et seq.), the criminal False Claims Law (42 U.S.C. § 1320a-7b(a)), all criminal laws relating to healthcare
fraud and abuse, including but not limited to 18 U.S.C. Sections 286 and 287, the healthcare fraud criminal provisions under the U.S.
Health Insurance Portability and Accountability Act of 1996 (“HIPAA”) (42 U.S.C. Section 1320d et seq.), the
exclusion laws (42 U.S.C. § 1320a-7), and the civil monetary penalties law (42 U.S.C. § 1320a-7a); (iii) HIPAA, as amended
by the Health Information Technology for Economic Clinical Health Act (42 U.S.C. Section 17921 et seq.); (iv) the regulations promulgated
pursuant to such laws; and (v) any other similar local, state, federal, or foreign laws (collectively, the “Health Care Laws”).
Neither the Company, nor to the Company’s knowledge, any of its officers, directors, employees or agents have engaged in activities
which are, as applicable, cause for false claims liability, civil penalties, or mandatory or permissive exclusion from Medicare, Medicaid,
or any other state or federal healthcare program. The Company has not received written notice or other correspondence of any claim, action,
suit, audit, survey, proceeding, hearing, enforcement, investigation, arbitration or other action (“Action”)
from any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is
in violation of any Health Care Laws, and, to the Company’s knowledge, no such Action is threatened. The Company is not a party
to and does not have any ongoing reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement,
monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental or regulatory
authority. Additionally, neither the Company, nor to the Company’s knowledge, any of its employees, officers or directors, has
been excluded, suspended or debarred from participation in any U.S. state or federal health care program or human clinical research or,
to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that could
reasonably be expected to result in debarment, suspension, or exclusion.

 

    	13

     

    

 

(jj)
The studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the Company were
and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls
pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the
Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder; the descriptions of the results of such studies,
tests and trials contained in the SEC Reports are, to the Company’s knowledge, accurate and complete in all material respects and
fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the SEC Reports, the Company is
not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or
trial results described or referred to in the SEC Reports when viewed in the context in which such results are described and the clinical
state of development; and, except to the extent disclosed in the SEC Reports, the Company has not received any notices or correspondence
from the FDA or any governmental or regulatory authority requiring the termination or suspension of any studies, tests or preclinical
or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications
in connection with the design and implementation of such trials.

 

(kk)
The Company has not received any notice from the Nasdaq Global Select Market regarding the delisting of the Common Stock. The Company
is in material compliance with all listing and maintenance requirements of Nasdaq on the date hereof.

 

(ll)
All United States federal income tax returns of the Company required by law to be filed have been filed and all taxes shown by such returns
or otherwise assessed, which are due and payable, have been paid, except assessments against which appeals have been or will be promptly
taken and as to which adequate reserves have been provided in conformity with GAAP. The United States federal income tax returns of the
Company through the fiscal year ended December 31, 2018 have been settled and no assessment in connection therewith has been made against
the Company. The Company has filed all other tax returns that are required to have been filed by it pursuant to applicable foreign, state,
local or other law except insofar as the failure to file such returns would not result in a Material Adverse Effect, and have paid all
taxes due pursuant to such returns or pursuant to any assessment received by the Company, except for such taxes, if any, as are being
contested in good faith and as to which adequate reserves have been established by the Company, or insofar as the failure to pay such
taxes would not result in a Material Adverse Effect. The charges, accruals and reserves on the books of the Company in respect of any
income and corporation tax liability for any years not finally determined are, in conformity with GAAP, adequate to meet any assessments
or re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not
result in a Material Adverse Effect.

 

(mm)
Except as disclosed in the SEC Reports, there are no contracts, agreements or understandings between the Company and any person that
would give rise to a valid claim against the Company or any Purchaser for a brokerage commission, finder’s fee or other like payment
in connection with the offering of the Securities contemplated hereby.

 

(nn)
Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2 of this Agreement, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers hereunder. The issuance
and sale of the Securities hereunder does not contravene the rules and regulations of Nasdaq.

 

    	14

     

    

 

3.2
Representations, Warranties and Covenants of the Purchasers. Each Purchaser, for itself and for no other Purchaser, hereby represents,
warrants and covenants to the Company and the Placement Agent as of the date hereof and as of the Closing:

 

(a)
Such Purchaser has all requisite legal and corporate or other power and capacity and has taken all requisite corporate or other action
to execute and deliver this Agreement, to purchase the Securities and to carry out and perform all of its obligations under this Agreement;
and (b) this Agreement constitutes the legal, valid and binding obligation of such Purchaser, enforceable against such Purchaser in accordance
with its terms, except (i) as limited by applicable bankruptcy, insolvency, reorganization or similar laws relating to or affecting the
enforcement of creditors’ rights generally and (ii) as limited by equitable principles generally.

 

(b)
At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on the date on which it exercises
any Warrants, it will be (i) either: (A) an “accredited investor” as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8),
(a)(9) or (a)(12) under the Securities Act, or (B) a “qualified institutional buyer” as defined in Rule 144A(a) under the
Securities Act, (ii) an Institutional Account as defined in Financial Industry Regulatory Authority Rule 4512(c), and (iii) a sophisticated
institutional investor, experienced in investing in private equity transactions and capable of evaluating investment risks independently,
both in general and with regard to all transactions and investment strategies involving a security or securities, including such Purchaser’s
participation in the transactions contemplated by this Agreement. Such Purchaser has determined based on its own independent review and
such professional advice as it deems appropriate that its purchase of the Securities and participation in the transactions contemplated
by this Agreement (i) are fully consistent with its financial needs, objectives and condition, (ii) comply and are fully consistent with
all investment policies, guidelines and other restrictions applicable to it, (iii) have been duly authorized and approved by all necessary
action, (iv) do not and will not violate or constitute a default under its charter, by-laws or other constituent document or under any
law, rule, regulation, agreement or other obligation by which it is bound and (v) are a fit, proper and suitable investment for such
Purchaser, notwithstanding the substantial risks inherent in investing in or holding the Securities. Such Purchaser is able to bear the
substantial risks associated with its purchase of the Securities, including but not limited to loss of its entire investment therein.

 

(c)
Such Purchaser has (i) received, reviewed and understood the offering materials made available to it in connection with the transactions
contemplated by this Agreement, (ii) had the opportunity to ask questions of and receive answers from the Company directly and (iii)
conducted and completed its own independent due diligence with respect to the transactions contemplated by this Agreement. Based on such
information as such Purchaser has deemed appropriate and without reliance upon the Placement Agent, such Purchaser has independently
made its own analysis and decision to purchase the Securities. Except for the representations, warranties and agreements of the Company
expressly set forth in this Agreement, such Purchaser is relying exclusively on its own sources of information, investment analysis and
due diligence (including professional advice it deems appropriate) with respect to the transactions contemplated by this Agreement, the
Securities and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including
but not limited to all business, legal, regulatory, accounting, credit and tax matters.

 

    	15

     

    

 

(d)
Such Purchaser is acquiring its entire beneficial ownership interest in the Securities, and upon exercise of the Warrants will acquire
the Warrant Shares issuable upon exercise of the Warrants, for its own account for investment purposes only and not with a view to any
distribution of the Securities in any manner that would violate the securities laws of the United States or any other jurisdiction. Such
Purchaser understands that the Securities have not been registered under the securities laws of the United States or any other jurisdiction
and that the Securities may not be resold or transferred in the United States or otherwise except in compliance with applicable law and
the restrictions on transfer set forth in the Transaction Documents.

 

(e)
Such Purchaser understands that the Securities being offered and sold to it in reliance on specific exemptions from the registration
requirements of United States federal and state securities laws and that the Company is relying in part upon the truth and accuracy of,
and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements and understandings of such
Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility of such Purchaser to acquire
the Securities. Such Purchaser further acknowledges and understands that the Securities may not be resold or otherwise transferred except
in a transaction registered under the Securities Act or unless an exemption from such registration is available.

 

(f)
Dispositions.

 

(i)
Such Purchaser will not, prior to the effectiveness of the Resale Registration Statement (as defined below), if then prohibited by law
or regulation other than pursuant to an available exemption under the Securities Act, sell, offer to sell, solicit offers to buy, dispose
of, loan, pledge or grant any right with respect to the Securities.

 

(ii)
As of the Closing Date, such Purchaser has not directly or indirectly, nor has any person acting on behalf of or pursuant to any understanding
with such Purchaser, engaged in any purchases or sales of the Company’s securities (including, without limitation, any Short Sales
involving the Company’s securities) since the time that such Purchaser was first contacted by the Company, the Placement Agent
or any other person regarding the transactions contemplated hereby. Such Purchaser covenants that neither it nor any person acting on
its behalf or pursuant to any understanding with it will engage in any purchases or sales of the Company’s securities (including,
without limitation, any Short Sales involving the Company’s securities) prior to the time that the transactions contemplated by
this Agreement are publicly disclosed.

 

(g)
Such Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant to this Agreement. Such Purchaser
understands that nothing in this Agreement or any other materials presented to such Purchaser in connection with the purchase and sale
of the Securities constitutes legal, tax or investment advice.

 

(h)
Such Purchaser will hold in confidence all information concerning this Agreement and the sale and issuance of the Securities until the
Company has made a public announcement concerning this Agreement and the sale and issuance of the Securities, which shall be made not
later than 9:30 am New York City time on the Trading Day immediately after the signing of this Agreement.

 

    	16

     

    

 

(i)
Purchaser understands that no United States federal or state agency or any other government or governmental agency has passed upon or
made any recommendation or endorsement of the Securities.

 

(j)
Legend.

 

(i)
Such Purchaser understands that the Securities shall bear a restrictive legend in substantially the following form (and a stop transfer
order may be placed against transfer of the certificates for the Securities):

 

“THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS
OF ANY STATE OF THE UNITED STATES OR IN ANY OTHER JURISDICTION. THE SECURITIES REPRESENTED HEREBY MAY NOT BE OFFERED, SOLD OR TRANSFERRED
IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS UNLESS OFFERED, SOLD OR TRANSFERRED
PURSUANT TO AN AVAILABLE EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THOSE LAWS.”

 

(ii)
The Company shall, at its sole expense, upon appropriate notice from any Purchaser stating that Registrable Shares (as defined below)
have been sold pursuant to an effective registration statement, timely prepare and deliver certificates or book-entry shares representing
the Securities to be delivered to a transferee pursuant to the registration statement, which certificates or book-entry shares shall
be free of any restrictive legends and in such denominations and registered in such names as such Purchaser may request. Further, the
Company shall, at its sole expense, cause its legal counsel or other counsel satisfactory to the transfer agent: (i) while the registration
statement is effective, to issue to the transfer agent a “blanket” legal opinion to allow (A) the legend on the Securities
to be removed, or (B) sales without restriction pursuant to the effective registration statement, and (ii) provide all other opinions
as may reasonably be required by the transfer agent in connection with the removal of legends. A Purchaser may request that the Company
remove, and the Company agrees to authorize the removal of, any legend from such Securities, following the delivery by a Purchaser to
the Company or the Company’s transfer agent of a legended certificate representing such Securities: (i) following any sale of such
Securities pursuant to Rule 144, (ii) if such Securities are eligible for sale under Rule 144(b)(1), or (iii) following the time that
the registration statement is declared effective. If a legend removal request is made pursuant to the foregoing, the Company will, no
later than two Trading Days following the delivery by a Purchaser to the Company or the Company’s transfer agent of a legended
certificate representing such Securities (or a request for legend removal, in the case of Securities issued in book-entry form), deliver
or cause to be delivered to such Purchaser a certificate representing such Securities that is free from all restrictive legends or an
equivalent book-entry position, as requested by the Purchaser. Certificates for Securities free from all restrictive legends may be transmitted
by the Company’s transfer agent to the Purchasers by crediting the account of the Purchaser’s prime broker with the Depository
Trust Company (“DTC”) as directed by such Purchaser. The Company warrants that the Securities shall otherwise
be freely transferable on the books and records of the Company as and to the extent provided in this Agreement. If a Purchaser effects
a transfer of the Securities in accordance with Section 3.2(j)(ii), the Company shall permit the transfer and shall promptly instruct
its transfer agent to issue one or more certificates or credit shares to the applicable balance accounts at DTC in such name and in such
denominations as specified by such Purchaser to effect such transfer. Such Purchaser hereby agrees that the removal of the restrictive
legend pursuant to this Section 3.2(j)(ii) is predicated upon the Company’s reliance that such Purchaser will sell any such
Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements,
or an exemption therefrom.

 

    	17

     

    

 

(k)
Immediately prior to the Closing, such Purchaser, together with its affiliates and any other persons acting as a group together with
such Purchaser and any of its affiliates, beneficially owned the number of shares of Common Stock set forth on such Purchaser’s
signature page attached hereto (as such ownership is calculated pursuant to the rules of Nasdaq).

 

(l)
If such Purchaser is not a United States person (as defined by Section 7701(a)(30) of the Internal Revenue Code), such Purchaser hereby
represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to
subscribe for the Securities or any use of this Agreement, including (a) the legal requirements within its jurisdiction for the purchase
of the Securities, (b) any foreign exchange restrictions applicable to such purchase or acquisition, (c) any government or other consents
that may need to be obtained, and (d) the income tax and other tax consequences, if any, that may be relevant to the purchase, holding,
redemption, sale or transfer of the Securities. Such Purchaser’s subscription and payment for and continued beneficial ownership
of the Securities will not violate any applicable securities or other laws of such Purchaser’s jurisdiction.

 

(m)
Acknowledgements Regarding Placement Agent by each Purchaser. Such Purchaser acknowledges and agrees that (a) the Placement Agent
is acting solely as the Company’s placement agent in connection with the transactions contemplated by this Agreement and is not
acting as an underwriter or in any other capacity and is not and will not be construed as a fiduciary for such Purchaser, the Company
or any other person or entity in connection with the transactions contemplated by this Agreement, (b) the Placement Agent have not made
and will not make any representation or warranty, whether express or implied, of any kind or character and has not provided any advice
or recommendation in connection with the transactions contemplated by this Agreement, (c) the Placement Agent will have no responsibility
with respect to (i) any representations, warranties or agreements made by any person or entity under or in connection with the transactions
contemplated by this Agreement or any of the documents furnished pursuant thereto or in connection therewith, or the execution, legality,
validity or enforceability (with respect to any person) or any thereof, or (ii) the business, affairs, financial condition, operations,
properties or prospects of, or any other matter concerning the Company or the transactions contemplated by this Agreement, and (d) the
Placement Agent shall have no liability or obligation (including without limitation, for or with respect to any losses, claims, damages,
obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by you, the Company or any other person
or entity), whether in contract, tort or otherwise, to such Purchaser, or to any person claiming through such Purchaser, in respect of
the transactions contemplated by this Agreement.

 

    	18

     

    

 

4.
REGISTRATION RIGHTS

 

4.1
Definitions. For the purpose of this Section 4:

 

(a)
the term “Resale Registration Statement” shall mean any registration statement required to be filed by Section
4.2 below, and shall include any preliminary prospectus, final prospectus, exhibit or amendment included in or relating to such registration
statements; and

 

(b)
the term “Registrable Shares” means the Shares and the Warrant Shares provided, however, that a security
shall cease to be a Registrable Share upon the earliest to occur of the following: (i) a Resale Registration Statement registering such
security under the Securities Act has been declared or becomes effective and such security has been sold or otherwise transferred by
the holder thereof pursuant to and in a manner contemplated by such effective Resale Registration Statement, (ii) such security is sold
pursuant to Rule 144 under circumstances in which any legend borne by such security relating to restrictions on transferability thereof,
under the Security Act or otherwise, is removed by the Company, (iii) such security is eligible to be sold pursuant to Rule 144 without
condition or restriction, including without any limitation as to volume of sales, and without the holder complying with any method of
sale requirements or notice requirements under Rule 144, or (iv) such security shall cease to be outstanding following its issuance.

 

4.2
Registration Procedures and Expenses. The Company shall:

 

(a)
file a Resale Registration Statement (the “Mandatory Registration Statement”) with the Commission on or before
August 12, 2022 (the “Filing Date”) to register all of the Registrable Shares on Form S-3 under the Securities
Act (providing for shelf registration of such Registrable Shares under Commission Rule 415). In the event that Form S-3 is not available
for the registration of the Registrable Shares, the Company shall register the resale of the Registrable Shares on such other form as
is available to the Company;

 

(b)
use its commercially reasonable efforts to cause such Mandatory Registration Statement to be declared effective as soon as practicable
and in any event on or before the Effectiveness Deadline, such efforts to include, without limiting the generality of the foregoing,
preparing and filing with the Commission any financial statements or other information that is required to be filed prior to the effectiveness
of such Mandatory Registration Statement;

 

(c)
notwithstanding anything contained in this Agreement to the contrary, in the event that the Commission limits the amount of Registrable
Shares or otherwise requires a reduction in the number of Registrable Shares that may be included and sold by the Purchasers in the Mandatory
Registration Statement (in each case, subject to Section 4.2(m)), then the Company shall prepare and file (i) within 10 Trading
Days of the first date or time that such excluded Registrable Shares may then be included in a Resale Registration Statement if the Commission
shall have notified the Company that certain Registrable Shares were not eligible for inclusion in the Resale Registration Statement
or (ii) in all other cases, within 20 days following the date that the Company becomes aware that such additional Resale Registration
Statement is required (the “Additional Filing Date”), a Resale Registration Statement (any such Resale Registration
Statement registering such excluded Registrable Shares, an “Additional Registration Statement” and, together
with the Mandatory Registration Statement, a “Resale Registration Statement”) to register any Registrable Shares
that have been excluded (or, if applicable, the maximum number of such excluded Registrable Shares that the Company is permitted to register
for resale on such Additional Registration Statement consistent with Commission guidance), if any, from being registered on the Mandatory
Registration Statement;

 

    	19

     

    

 

(d)
not less than two (2) Trading Days prior to the filing of a Resale Registration Statement or any related prospectus or any amendment
or supplement thereto, furnish via email to those Purchasers who have supplied the Company with email addresses copies of all such documents
proposed to be filed, which documents (other than any document that is incorporated or deemed to be incorporated by reference therein)
will be subject to the review of such Purchasers. The Company shall reflect in each such document when so filed with the Commission such
comments regarding the Purchasers and the plan of distribution as the Purchasers may reasonably and promptly propose no later than two
(2) Trading Days after the Purchasers have been so furnished with copies of such documents as aforesaid.

 

(e)
use its commercially reasonable efforts to cause any such Additional Registration Statement to be declared effective as promptly as practicable
following the Additional Filing Date, such efforts to include, without limiting the generality of the foregoing, preparing and filing
with the Commission any financial statements or other information that is required to be filed prior to the effectiveness of any such
Additional Registration Statement;

 

(f)
promptly prepare and file with the Commission such amendments and supplements to such Resale Registration Statements and the prospectus
used in connection therewith as may be necessary to keep such Resale Registration Statements continuously effective and free from any
material misstatement or omission to state a material fact therein until termination of such obligation as provided in Section 4.7
below, subject to the Company’s right to suspend pursuant to Section 4.6;

 

(g)
furnish to the Purchasers such number of copies of prospectuses in conformity with the requirements of the Securities Act and such other
documents as the Purchasers may reasonably request, in order to facilitate the public sale or other disposition of all or any of the
Registrable Shares by the Purchasers;

 

(h)
file such documents as may be required of the Company for normal securities law clearance for the resale of the Registrable Shares in
such states of the United States as may be reasonably requested by the Purchasers and use its commercially reasonable efforts to maintain
such blue sky qualifications during the period the Company is required to maintain effectiveness of the Resale Registration Statements;
provided, however, that the Company shall not be required in connection with this Section 4.2(h) to qualify as a foreign
corporation or execute a general consent to service of process in any jurisdiction in which it is not now so qualified or has not so
consented;

 

(i)
upon notification by the Commission that that the Resale Registration Statement has been declared effective by the Commission, the Company
shall file the final prospectus under Rule 424 of the Securities Act (“Rule 424”) within the applicable time
period prescribed by Rule 424;

 

    	20

     

    

 

(j)
advise the Purchasers promptly (and in any event within two (2) Trading Days thereof):

 

(i)
of the effectiveness of the Resale Registration Statement or any post-effective amendments thereto;

 

(ii)
of any request by the Commission for amendments to the Resale Registration Statement or amendments to the prospectus or for additional
information relating thereto;

 

(iii)
of the issuance by the Commission of any stop order suspending the effectiveness of the Resale Registration Statement under the Securities
Act or of the suspension by any state securities commission of the qualification of the Registrable Shares for offering or sale in any
jurisdiction, or the initiation of any proceeding for any of the preceding purposes; and

 

(iv)
of the existence of any fact and the happening of any event that makes any statement of a material fact made in the Resale Registration
Statement, the prospectus and amendment or supplement thereto, or any document incorporated by reference therein, untrue, or that requires
the making of any additions to or changes in the Resale Registration Statement or the prospectus in order to make the statements therein
not misleading;

 

(k)
cause all Registrable Shares to be listed on each securities exchange, if any, on which equity securities by the Company are then listed;

 

(l)
bear all expenses in connection with the procedures in paragraphs (a) through (l) of this Section 4.2 and the registration of
the Registrable Shares on such Resale Registration Statement and the satisfaction of the blue sky laws of such states; and

 

(m)
not, from the date hereof until the effective date of the Mandatory Registration Statement, prepare and file with the Commission a registration
statement relating to an offering for its own account or the account of others under the Securities Act of any of its equity securities,
other than any registration statement or post-effective amendment to a registration statement (or supplement thereto) related to the
Company’s employee benefit plans registered on Form S-8).

 

    	21

     

    

 

4.3
Effect of Failure to File and Obtain and Maintain Effectiveness of Registration Statement. If: (i) the Resale Registration Statement
is not filed with the SEC on or prior to the Filing Date, (ii) the Registration Statement is not declared effective by the SEC (or otherwise
does not become effective) for any reason on or prior to the Effectiveness Deadline, (iii) after its effective date (A) the Resale Registration
Statement ceases for any reason (including without limitation by reason of a stop order, or the Company’s failure to update the
Resale Registration Statement), to remain continuously effective as to all Registrable Shares included in the Resale Registration Statement
or (B) the Company suspends the use of the prospectus contained in the Resale Registration Statement, or (iv) the Company fails to satisfy
the current public information requirement pursuant to Rule 144(c)(1) as a result of which the Purchasers are unable to sell Registrable
Shares without restriction under Rule 144 (or any successor thereto) and fails to cure any such failure to satisfy the Rule 144(c)(1)
requirement within 15 business days following the date upon which the Purchaser notifies the Company in writing that such Purchaser is
unable to sell Registrable Shares as a result thereof, (any such failure or breach in clauses (i) through (iv) above being referred to
as an “Event,” and the date on which such Event occurs, being referred to as an “Event Date”), then in addition
to any other rights the Purchasers may have hereunder or under applicable law, on each such Event Date and on each monthly anniversary
of each such Event Date (if the applicable Event shall not have been cured by such date) until the earlier of (1) the applicable Event
is cured or (2) the Registrable Shares are eligible for resale pursuant to Rule 144 without manner of sale or volume restrictions, the
Company shall pay to each Purchaser an amount in cash, as partial liquidated damages and not as a penalty (“Liquidated Damages”),
equal to one percent (1.0%) of the aggregate purchase price paid by such Purchaser pursuant to this Agreement for any Registrable Shares
then held by such Purchaser. If the Company fails to pay any Liquidated Damages pursuant to this Section 4.3 in full within five (5)
business days after the date payable, the Company will pay interest thereon at a rate of one percent (1.0%) per month (or such lesser
maximum amount that is permitted to be paid by applicable law) to the Purchaser, accruing daily from the date such Liquidated Damages
are due until such amounts, plus all such interest thereon, are paid in full. The Liquidated Damages pursuant to the terms hereof shall
apply on a daily pro-rata basis for any portion of a month prior to the cure of an Event, except in the case of the first Event Date.

 

4.4
Rule 415; Cutback.

 

If
at any time the Staff takes the position that the offering of some or all of the Registrable Shares in the Resale Registration Statement
is not eligible to be made on a delayed or continuous basis under the provisions of Rule 415 under the Securities Act or requires any
Purchaser to be named as an “underwriter,” the Company shall (in consultation with legal counsel to the lead Purchaser) use
its commercially reasonable efforts to persuade the Commission that the offering contemplated by the Resale Registration Statement is
a valid secondary offering and not an offering “by or on behalf of the issuer” as defined in Rule 415 and that none of the
Purchasers is an “underwriter.” In the event that, despite the Company’s commercially reasonable efforts and compliance
with the terms of this Section 4.4, the Staff refuses to alter its position, the Company shall (i) remove from the Resale Registration
Statement such portion of the Registrable Shares (the “Cut Back Shares”) and/or (ii) agree to such restrictions
and limitations on the registration and resale of the Registrable Shares as the Staff may require to assure the Company’s compliance
with the requirements of Rule 415 (collectively, the “SEC Restrictions”); provided, however, that the Company
shall not agree to name any Purchaser as an “underwriter” in such Resale Registration Statement without the prior written
consent of such Purchaser. Any cutback imposed on the Purchasers pursuant to this Section 4.4 shall be allocated among the Purchasers
on a pro rata basis, unless the SEC Restrictions otherwise require or provide or the Purchasers holding a majority of the Registrable
Shares otherwise agree. No liquidated damages shall accrue as to any Cut Back Shares until such date as the Company is able to effect
the registration of such Cut Back Shares in accordance with any SEC Restrictions (such date, the “Restriction Termination
Date” of such Cut Back Shares). From and after the Restriction Termination Date applicable to any Cut Back Shares, all
of the provisions of this Section 4 shall again be applicable to such Cut Back Shares; provided, however, that (x) the filing
deadline for the Resale Registration Statement including such Cut Back Shares shall be 10 Trading Days after such Restriction Termination
Date, and (y) the Effectiveness Deadline with respect to such Cut Back Shares shall be the 60th day immediately after the
Restriction Termination Date or the 90th day if the Staff reviews such Resale Registration Statement (but in any event no
later than two Trading Days from the Staff indicating it has no further comments on such Resale Registration Statement).

 

    	22

     

    

 

4.5
Indemnification.

 

(a)
The Company agrees to indemnify and hold harmless each Purchaser and its affiliates, partners, members, officers, directors, agents and
representatives, and each person, if any, who controls such Purchaser within the meaning of Section 15 of the Securities Act or Section
20 the Exchange Act (each, a “Purchaser Party” and collectively the “Purchaser Parties”),
to the fullest extent permitted by applicable law, from and against any losses, claims, damages or liabilities (collectively, “Losses”)
to which they may become subject (under the Securities Act or otherwise) insofar as such Losses (or actions or proceedings in respect
thereof) arise out of, or are based upon, any material breach of this Agreement by the Company or any untrue statement or alleged untrue
statement of a material fact contained in the Resale Registration Statement or any omission or alleged omission to state therein a material
fact required to be stated therein or necessary to make the statements therein, in light of the circumstances under which they were made,
not misleading or arise out of any failure by the Company to fulfill any undertaking included in the Resale Registration Statement and
the Company will, as incurred, reimburse the Purchaser Parties for any legal or other expenses reasonably incurred in investigating,
defending or preparing to defend any such action, proceeding, or claim; provided, however, that the Company shall not be liable
in any such case to the extent that such Loss arises out of, or is based upon: (i) an untrue statement or omission or alleged untrue
statement or omission made in such Resale Registration Statement in reliance upon and in conformity with written information furnished
to the Company by or on behalf of such Purchaser specifically for use in preparation of the Resale Registration Statement; or (ii) any
breach of this Agreement by such Purchaser; provided further, however, that the Company shall not be liable to any Purchaser Party
(or any partner, member, officer, director or controlling person of the Purchasers) to the extent that any such Loss is caused by an
untrue statement or omission or alleged untrue statement or omission made in any preliminary prospectus if either (i) (A) such Purchaser
failed to send or deliver a copy of the final prospectus with or prior to, or such Purchaser failed to confirm that a final prospectus
was deemed to be delivered prior to (in accordance with Rule 172 of the Securities Act), the delivery of written confirmation of the
sale by such Purchaser to the person asserting the claim from which such Loss resulted and (B) the final prospectus corrected such untrue
statement or omission, (ii) (X) such untrue statement or omission is corrected in an amendment or supplement to the prospectus and (Y)
having previously been furnished by or on behalf of the Company with copies of the prospectus as so amended or supplemented or notified
by the Company that such amended or supplemented prospectus has been filed with the Commission, in accordance with Rule 172 of the Securities
Act, such Purchaser thereafter fails to deliver such prospectus as so amended or supplemented, with or prior to or a Purchaser fails
to confirm that the prospectus as so amended or supplemented was deemed to be delivered prior to (in accordance with Rule 172 of the
Securities Act), the delivery of written confirmation of the sale by such Purchaser to the person asserting the claim from which such
Loss resulted or (iii) such Purchaser sold Registrable Shares in violation of such Purchasers’ covenants contained in Section
3.2 of this Agreement.

 

    	23

     

    

 

(b)
Each Purchaser agrees, severally and not jointly, to indemnify and hold harmless the Company and its officers, directors, affiliates,
agents and representatives and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or
Section 20 of the Exchange Act (each a “Company Party” and collectively the “Company Parties”),
from and against any Losses to which the Company Parties may become subject (under the Securities Act or otherwise), insofar as such
Losses (or actions or proceedings in respect thereof) arise out of, or are based upon, any material breach of this Agreement by such
Purchaser or untrue statement or alleged untrue statement of a material fact contained in the Resale Registration Statement (or any omission
or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein, in light
of the circumstances under which they were made, not misleading in each case, on the effective date thereof), if, and only to the extent,
such untrue statement or omission or alleged untrue statement or omission was made in reliance upon and in conformity with written information
furnished by or on behalf of such Purchaser specifically for use in preparation of the Resale Registration Statement, and each Purchaser,
severally and not jointly, will reimburse each Company Party for any legal or other expenses reasonably incurred in investigating, defending
or preparing to defend any such action, proceeding, or claim; provided, however, that in no event shall any indemnity under this
Section 4.5(b) be greater in amount than the dollar amount of the net proceeds received by such Purchaser upon its sale of the
Registrable Shares included in the Resale Registration Statement giving rise to such indemnification obligation.

 

(c)
Promptly after receipt by any indemnified person of a notice of a claim or the beginning of any action in respect of which indemnity
is to be sought against an indemnifying person pursuant to this Section 4.5, such indemnified person shall notify the indemnifying
person in writing of such claim or of the commencement of such action, and, subject to the provisions hereinafter stated, in case any
such action shall be brought against an indemnified person and such indemnifying person shall have been notified thereof, such indemnifying
person shall be entitled to participate therein, and, to the extent that it shall wish, to assume the defense thereof, with counsel reasonably
satisfactory to such indemnified person. After notice from the indemnifying person to such indemnified person of its election to assume
the defense thereof, such indemnifying person shall not be liable to such indemnified person for any legal expenses subsequently incurred
by such indemnified person in connection with the defense thereof; provided, however, that if there exists or shall exist a conflict
of interest that would make it inappropriate in the reasonable judgment of the indemnified person for the same counsel to represent both
the indemnified person and such indemnifying person or any affiliate or associate thereof, the indemnified person shall be entitled to
retain its own counsel at the expense of such indemnifying person; provided, further, that no indemnifying person shall be responsible
for the fees and expense of more than one separate counsel for all indemnified parties. The indemnifying party shall not settle an action
without the consent of the indemnified party, which consent shall not be unreasonably withheld.

 

(d)
If after proper notice of a claim or the commencement of any action against the indemnified party, the indemnifying party does not choose
to participate, then the indemnified party shall assume the defense thereof and upon written notice by the indemnified party requesting
advance payment of a stated amount for its reasonable defense costs and expenses, the indemnifying party shall advance payment for such
reasonable defense costs and expenses (the “Advance Indemnification Payment”) to the indemnified party. In
the event that the indemnified party’s actual defense costs and expenses exceed the amount of the Advance Indemnification Payment,
then upon written request by the indemnified party, the indemnifying party shall reimburse the indemnified party for such difference;
in the event that the Advance Indemnification Payment exceeds the indemnified party’s actual costs and expenses, the indemnified
party shall promptly remit payment of such difference to the indemnifying party.

 

    	24

     

    

 

(e)
If the indemnification provided for in this Section 4.5 is held by a court of competent jurisdiction to be unavailable to an indemnified
party with respect to any losses, claims, damages or liabilities referred to herein, the indemnifying party, in lieu of indemnifying
such indemnified party thereunder, shall to the extent permitted by applicable law contribute to the amount paid or payable by such indemnified
party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the
indemnifying party on the one hand and of the indemnified party on the other, as well as any other relevant equitable considerations;
provided, that in no event shall any contribution by an indemnifying party hereunder be greater in amount than the dollar amount of the
proceeds received by such indemnifying party upon the sale of such Registrable Shares.

 

4.6
Prospectus Suspension. Each Purchaser acknowledges that there may be times when the Company must suspend the use of the prospectus
forming a part of the Resale Registration Statement until such time as an amendment to the Resale Registration Statement has been filed
by the Company and declared effective by the Commission, or until such time as the Company has filed an appropriate report with the Commission
pursuant to the Exchange Act. Each Purchaser hereby covenants that it will not sell any Registrable Shares pursuant to said prospectus
during the period commencing at the time at which the Company gives the Purchasers notice of the suspension of the use of said prospectus
and ending at the time the Company gives the Purchasers notice that the Purchasers may thereafter effect sales pursuant to said prospectus;
provided, that such suspension periods shall in no event exceed 30 days in any 12 month period and that, in the good faith judgment of
the Company’s board of directors, the Company would, in the absence of such delay or suspension hereunder, be required under state
or federal securities laws to disclose any corporate development, a potentially significant transaction or event involving the Company,
or any negotiations, discussions, or proposals directly relating thereto, in either case the disclosure of which would reasonably be
expected to have a Material Adverse Effect upon the Company or its stockholders.

 

4.7
Termination of Obligations. The obligations of the Company pursuant to Section 4.2 hereof shall cease and terminate, with
respect to any Registrable Shares, upon the earlier to occur of (a) such time such Registrable Shares have been resold, or (b) such time
as such Registrable Shares no longer remain Registrable Shares pursuant to Section 4.1(b) hereof.

 

4.8
Reporting Requirements.

 

(a)
With a view to making available the benefits of certain rules and regulations of the Commission that may at any time permit the sale
of the Securities to the public without registration or pursuant to a registration statement on Form S-3, the Company agrees to use commercially
reasonable efforts to:

 

(i)
make and keep public information available, as those terms are understood and defined in Rule 144;

 

    	25

     

    

 

(ii)
file with the Commission in a timely manner all reports and other documents required of the Company under the Securities Act and the
Exchange Act; and

 

(iii)
so long as a Purchaser owns Registrable Shares, to furnish to such Purchaser upon request (A) a written statement by the Company as to
whether it is in compliance with the reporting requirements of Rule 144, the Securities Act and the Exchange Act, or whether it is qualified
as a registrant whose securities may be resold pursuant to Commission Form S-3, (B) a copy of the most recent annual or quarterly report
of the Company and such other reports and documents so filed by the Company and (C) such other information as may be reasonably requested
to permit the Purchaser to sell such securities pursuant to Rule 144.

 

4.9
Blue Sky. The Company shall obtain and maintain all necessary blue sky law permits and qualifications, or secured exemptions therefrom,
required by any state for the offer and sale of Registrable Shares.

 

5.
OTHER AGREEMENTS OF
THE PARTIES

 

5.1
Integration. Except as contemplated by the terms of this Agreement, the Company shall not sell, offer for sale or solicit offers
to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the Securities Act) that would be integrated with
the offer or sale of the Securities such that the rules of Nasdaq would require shareholder approval of this transaction prior to the
closing of such other transaction unless shareholder approval is obtained before the closing of such subsequent transaction.

 

5.2
Securities Laws Disclosure; Publicity. The Company shall: (a) issue a press release not later than 9:30 am New York City time on
the Trading Day immediately after the signing of this Agreement disclosing the material terms of the transactions contemplated hereby
which shall have been previously reviewed by counsel for the Placement Agent (the “Press Release”), and (b)
by 5:30 p.m. (New York City time) on the fourth Trading Day following the date hereof, file a Current Report on Form 8-K disclosing the
material terms of the transactions contemplated hereby which shall have been previously reviewed by counsel for the Placement Agent.
From and after the issuance of the Press Release, no Purchaser shall be in possession of any material, non-public information received
from the Company or any of their respective officers, directors or employees that is not disclosed in the Press Release, other than such
Purchasers who have consented to the receipt of material, non-public information and agreed with the Company to keep such information
confidential. Subject to the foregoing, neither the Company nor any Purchaser shall issue any press releases or any other public statements
with respect to the transactions contemplated hereby except as may be reviewed and approved by the Company and counsel to the Placement
Agent; provided, however, that the Company shall be entitled, without the prior approval of any Purchaser, to make any
press release or other public disclosure with respect to the transactions contemplated hereby.

 

    	26

     

    

 

5.3
Non-Public Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction
Documents, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or
its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information,
unless prior thereto such Purchaser shall have consented to the receipt of such information and agreed with the Company to keep such
information confidential.

 

5.4
Use of Proceeds. The Company will use the proceeds from the offering to continue to develop and commercialize its assets, to pursue
strategic partnerships and for general corporate purposes.

 

5.5
Reservation of Common Stock. As of the date hereof, the Company has reserved and the Company shall continue to reserve and keep available
at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue
the Shares and the Warrant Shares pursuant to any exercise of the Warrants.

 

5.6
Nasdaq Listing. In the time and manner required by the Nasdaq, the Company shall prepare and file with Nasdaq an additional shares
listing application covering all of the Securities.

 

5.7
Equal Treatment of Purchasers. No consideration (including any modification of any Transaction Document) shall be offered or paid
to any person to amend or consent to a waiver or modification of any provision of the Transaction Documents unless the same consideration
is also offered to all of the parties to the Transaction Documents. For clarification purposes, this provision constitutes a separate
right granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat
the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with respect to the
purchase, disposition or voting of Securities or otherwise. 

 

5.8
Restriction on Sales of Securities.

 

(a)
During a period of 45 days from the effective date of the Mandatory Registration Statement, the Company will not, without the prior written
consent of the Purchasers, (i) directly or indirectly, offer, pledge, sell, contract to sell, sell any option or contract to purchase,
purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares
of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock or file any registration statement
under the Securities Act with respect to any of the foregoing, (ii) enter into any swap or any other agreement or any transaction that
transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap
or transaction described in clause (i) or (ii) above is to be settled by delivery of Common Stock or such other securities, in cash or
otherwise or (iii) publicly announce an intention to effect any such swap, agreement or other transaction described in clauses (i) and
(ii). The foregoing sentence shall not apply to (A) the Securities to be sold hereunder; (B) any shares of Common Stock issued by the
Company upon the exercise of an option or warrant or the conversion of a convertible security; (C) any shares of Common Stock issued
or options to purchase Common Stock granted pursuant to employee benefit plans of the Company; (D) any shares of Common Stock issued
pursuant to any non-employee director stock plan or dividend reinvestment plan; (E) the filing by the Company of any registration statement
on Form S-8 or a successor form thereto; (F) the filing by the Company of the Mandatory Registration Statement; (G) sales of Common Stock
pursuant to the Sales Agreement between the Company, SVB Leerink LLC and Cantor Fitzgerald & Co., dated February 26, 2021; or (H)
any issuances of Common Stock or securities convertible into Common Stock if such issuance is issued at a premium to the most recent
closing price of the Common Stock on the Nasdaq Stock Market.

 

    	27

     

    

 

(b)
During a period of 45 days from the effective date of the Mandatory Registration Statement, the directors and executive officers will
not, without the prior written consent of the Purchasers, directly or indirectly, (i) offer, pledge, sell, contract to sell, sell any
option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant for the sale of, or otherwise
dispose of or transfer any shares of Common Stock or any securities convertible into or exchangeable or exercisable for Common Stock,
whether now owned or hereafter acquired by any director or executive officer or with respect to which the undersigned has or hereafter
acquires the power of disposition (collectively, the “Lock-Up Securities”), or exercise any right with respect
to the registration of any of the Lock-Up Securities, or file or cause to be filed any registration statement in connection therewith,
under the Securities Act or (ii) enter into any swap or any other agreement or any transaction that transfers, in whole or in part, directly
or indirectly, the economic consequence of ownership of the Lock-Up Securities, whether any such swap or transaction is to be settled
by delivery of Common Stock or other securities, in cash or otherwise. Notwithstanding the foregoing, the undersigned may transfer Lock-Up
Securities without the prior written consent of the Purchasers:

 

(i)
as a bona fide gift or gifts;

 

(ii)
to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned (for purposes of this lock-up
agreement, “immediate family” shall mean any relationship by blood, marriage or adoption, not more remote than first cousin);

 

(iii)
as a distribution or other transfer by a partnership to its partners or former partners or by a limited liability company to its members
or retired members or by a corporation to its stockholders or former stockholders or to any wholly-owned subsidiary of such corporation;

 

(iv)
to the undersigned’s affiliates or to any investment fund or other entity controlled or managed by the undersigned;

 

(v)
pursuant to a qualified domestic relations order or in connection with a divorce settlement;

 

(vi)
by will or intestate succession upon the death of the undersigned; or

 

(vii)
to the Company in satisfaction of any tax withholding obligation.

 

    	28

     

    

 

Furthermore,
no provision in this letter shall be deemed to restrict or prohibit (1) the transfer of the undersigned’s Lock-Up Securities to
the Company in connection with the termination of the undersigned’s services to the Company; (2) the exercise or exchange by the
undersigned of any option or warrant to acquire any shares of Common Stock or options to purchase shares of Common Stock, in each case
for cash or on a “cashless” or “net exercise” basis, pursuant to any stock option, stock bonus or other stock
plan or arrangement; provided, however, that the underlying shares of Common Stock shall continue to be subject to the restrictions on
transfer set forth in this letter and that any filing under Section 16 of the Exchange Act made in connection with such exercise or exchange
shall clearly indicate in the footnotes thereto that (a) the filing relates to the circumstances described in this clause (2) and (b)
no shares were sold by the reporting person; and (3) the transfer of Lock-Up Securities upon the completion of a bona fide third-party
tender offer, merger, consolidation or other similar transaction made to all holders of the Company’s securities involving a change
of control of the Company; provided, however, that in the event that such tender offer, merger, consolidation or other such transaction
is not completed, such securities held by the undersigned shall remain subject to the restrictions on transfer set forth in this letter.

 

Notwithstanding
anything herein to the contrary, nothing herein shall prevent the undersigned from establishing a 10b5-1 trading plan that complies with
Rule 10b5-1 under the Exchange Act (“10b5-1 Trading Plan”) or from amending an existing 10b5-1 Trading Plan
so long as there are no sales of Lock-Up Securities under any such 10b5-1 Trading Plan; and provided that, the establishment of a 10b5-1
Trading Plan or the amendment of a 10b5-1 Trading Plan shall only be permitted if (i) the establishment or amendment of such plan is
not required to be reported in any public report or filing with the Securities Exchange Commission, or otherwise and (ii) the undersigned
does not otherwise voluntarily effect any public filing or report regarding the establishment or amendment of such plan.

 

5.9
Participation Rights.

 

(a)
If the Company proposes to undertake an offering of shares of Common Stock, or any instruments convertible into shares of Common Stock,
the Company shall, within a reasonable period of time preceding the consummation of the offering, offer the Purchaser the opportunity
to purchase such shares of Common Stock, or such instruments convertible into shares of Common Stock, as applicable, to be sold in the
offering (without regard to the exercise of any over-allotment option) at the same price per security at which the securities offered
in the offering are being offered to investors before excluding underwriters’ discounts and commissions or placement agent fees,
as applicable (the “Offering Price”) and otherwise on terms at least as favorable as those granted to any other
participant in the offering (such right, the “Offering Participation Right”). If the Purchaser exercises its
Offering Participation Right, the Purchaser shall have the right, but not the obligation, to purchase up to such number of such shares
of Common Stock, or such instruments convertible into shares of Common Stock, as applicable, that would enable the Purchaser to retain
the Purchaser’s ownership interest as it existed prior to the offering. The Offering Participation Right shall terminate and expire
on the date that is three years after the Closing Date.

 

    	29

     

    

 

(b)
Notwithstanding the foregoing, in the event that (i) the Company is advised by the SEC, the Financial Industry Regulatory Authority (“FINRA”),
any stock exchange on which the Company’s shares are to be traded (“Exchange”) or any other regulatory
body (or any of their staffs), or (ii) outside counsel for each of the Company, the Company’s underwriters, and the Purchaser reasonably
determine that the offering or sale of such securities to the Purchaser as described above in this Section 5.9 would violate any federal
or state securities laws or the rules or regulations of the SEC, FINRA, Exchange, or any other regulatory body, then the Company shall
offer to the Purchaser the right to purchase in a separate private placement (which shall be conducted, in whole or in part, concurrently
with the offering and the closing of which shall be contingent on the closing of the offering) up to that number of shares of common
stock that the Purchaser would have been entitled to purchase pursuant to Section 5.9, at the Offering Price. For the avoidance of doubt,
the parties agree that the Purchaser will not be required to enter into any “market stand-off,” “lock up” or
similar agreement that would restrict any transactions related to any securities purchased by the Purchaser pursuant to Section 5.9 of
this Agreement.

 

(c)
All offers to be made to the Purchaser pursuant to this Agreement shall be conducted in compliance with all federal and state securities
laws and regulations and all applicable rules, regulations and policies of the SEC, any exchange on which the Company’s shares
are to be listed, or any other regulatory body. This Agreement does not constitute an offer to sell securities of the Company in an offering.
Any offering of the Company’s securities in an offering will only be made pursuant to a prospectus filed with the SEC.

 

(d)
Notwithstanding anything to the contrary herein, the Purchaser shall not be able to exercise its Offering Participation Right if the
Purchaser’s exercise of such Offering Participation Right would result in the offering requiring approval by shareholders of the
Company.

 

6.
MISCELLANEOUS

 

6.1
Termination. This Agreement may be terminated by any Purchaser, as to such Purchaser’s obligations hereunder only and without
any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice to the other parties, if the
Closing has not been consummated within ten calendar days from the Effective Date through no fault of such Purchaser; provided, however,
that no such termination will affect the right of any party to sue for any breach by the other party (or parties).

 

6.2
Fees and Expenses. Except as expressly set forth in the Transaction Documents or the Engagement Letter to the contrary, each party
shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such
party incident to the negotiation, preparation, execution, delivery and performance of this Agreement. Notwithstanding the foregoing,
the Company shall pay all transfer agent fees, stamp taxes and other taxes and duties levied in connection with the delivery of any Securities
to the Purchasers.

 

6.3
Entire Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements and understandings, oral or written, with respect
to such subject matter, which the parties acknowledge have been merged into such documents, exhibits and schedules.

 

6.4
Notices. Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing
and shall be deemed given and effective upon actual receipt via mail, courier or confirmed email by the party to whom such notice is
required to be given. The address for such notices and communications shall be as set forth on the signature pages attached hereto.

 

    	30

     

    

 

6.5
Amendments; Waivers. No provision of this Agreement may be waived or amended except in a written instrument signed, in the case of
an amendment, by (a) the Company and (b) Purchasers holding at least a majority of the Securities sold in the Closing (as a single class
on an as-converted to Common Stock basis) and then-held by a Purchaser or, in the case of a waiver, by the party against whom enforcement
of any such waived provision is sought; provided that if any amendment, disproportionately and adversely impacts a Purchaser (or group
of Purchasers) in any material respect, the consent of such disproportionately impacted Purchaser (or group of Purchasers) shall also
be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be
a continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement
hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise of any such right.

 

6.6
Headings. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof.

 

6.7
Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their permitted successors
and assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each
Purchaser (other than by merger). The Purchasers may not assign this Agreement or any rights or obligations hereunder without the prior
written consent of the Company (other than by merger).

 

6.8
Third-Party Beneficiaries; Reliance by the Placement Agent. The parties agree and acknowledge that the Placement Agents shall be
the third party beneficiaries of and may rely on, the representations, warranties, agreements and covenants of the Company contained
in this Agreement (including the representations and warranties of the Company in Section 3.1) and the representations warranties
and covenants of the respective Purchasers contained in this Agreement (including the representations, warranties and covenants of the
Purchasers in Section 3.2 and Section 5.2), as if such representations, warranties, agreements and covenants, as applicable,
were made directly to the Placement Agent. This Agreement is intended for the benefit of the parties hereto, as well as to the Placement
Agent to the extent it is a third party beneficiary pursuant to this Section 6.8, and its respective permitted successors and
assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other person, except as otherwise set forth in
Section 4.5(a), this Section 6.8 and Section 6.9. The parties further agree that the Placement Agent may rely on or, if
the Placement Agent so requests, be specifically named as addressees of, the legal opinion to be delivered pursuant to Section 2.2(b)(v)
of this Agreement.

 

    	31

     

    

 

6.9
Exculpation of Placement Agent. Each party hereto agrees for the express benefit of the Placement Agent, its affiliates and its representatives
that:

 

(a)
Neither the Placement Agent nor any of its affiliates or any of its representatives (1) has any duties or obligations other than those
specifically set forth herein or in the Engagement Letter; (2) shall be liable for any improper payment made in accordance with the information
provided by the Company; (3) makes any representation or warranty, or has any responsibilities as to the validity, accuracy, value or
genuineness of any information, certificates or documentation delivered by or on behalf of the Company pursuant to this Agreement or
the Transaction Documents or in connection with any of the transactions contemplated by this Agreement, including any offering or marketing
materials; or (4) shall be liable (x) for any action taken, suffered or omitted by any of them in good faith and reasonably believed
to be authorized or within the discretion or rights or powers conferred upon it by this Agreement or any Transaction Document or (y)
for anything which any of them may do or refrain from doing in connection with this Agreement or any Transaction Document, except for
such party’s own gross negligence, willful misconduct or bad faith.

 

(b)
The Placement Agent, it’s respective affiliates and it’s respective representatives shall be entitled to (1) rely on, and
shall be protected in acting upon, any certificate, instrument, opinion, notice, letter or any other document or security delivered to
any of them by or on behalf of the Company, and (2) be indemnified by the Company for acting as Placement Agent hereunder pursuant the
indemnification provisions set forth in the Engagement Letter.

 

6.10
Governing Law. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents shall
be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles
of conflicts of law thereof. Each party agrees that all legal proceedings concerning the interpretations, enforcement and defense of
the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective
affiliates, directors, officers, shareholders, employees or agents) shall be commenced exclusively in the state and federal courts sitting
in the State of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting
in the State of New York for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated
hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably waives,
and agrees not to assert in any suit, action, or proceeding, any claim that it is not personally subject to the jurisdiction of any such
court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably
waives personal service of process and consents to process being served in any such suit, action or proceeding by mailing a copy thereof
via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices
to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing
contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party
shall commence an action or proceeding to enforce any provisions of the Transaction Documents, then the prevailing party in such action
or proceeding shall be reimbursed by the other party for its reasonable attorneys’ fees and other costs and expenses incurred with
the investigation, preparation and prosecution of such action or proceeding.

 

6.11
Execution. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and
the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it
being understood that the parties need not sign the same counterpart. In the event that any signature on this Agreement is delivered
by facsimile transmission or by e-mail delivery of a “.pdf” format data file, such signature shall create a legally valid
and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such
facsimile or “.pdf” signature page were an original thereof.

 

    	32

     

    

 

6.12
Severability. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain
in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall use their commercially
reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated
by such term, provision, covenant or restriction. It is hereby stipulated and declared to be the intention of the parties that they would
have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared
invalid, illegal, void or unenforceable.

 

6.13
Rescission and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions
of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction
Document and the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may
rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights.

 

6.14
Replacement of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the
Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation),
or in lieu of and substitution therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to
the Company of such loss, theft or destruction and customary and reasonable indemnity or bond, if requested. The applicant for a new
certificate or instrument under such circumstances shall also pay any reasonable third-party costs (including customary indemnity) associated
with the issuance of such replacement Securities.

 

6.15
Remedies. The Company shall be entitled to exercise all rights provided herein or granted by law, including recovery of damages,
for any breach of the Transaction Documents.

 

6.16
Independent Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document
are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
or non-performance of the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other
Transaction Document, and no action taken by any Purchaser pursuant thereto, shall be deemed to constitute the Purchasers as a partnership,
an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert
or as a group with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Purchaser shall be
entitled to independently protect and enforce its rights, including without limitation, the rights arising out of this Agreement or out
of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional party in any
proceeding for such purpose. Each Purchaser understands that the Placement Agent has acted solely as the agent of the Company in this
placement of the Securities and such Purchaser has not relied on the business or legal advice of the Placement Agent or any of its agents,
counsel or affiliates in making its investment decision hereunder, and confirms that none of such persons has made any representations
or warranties to such Purchaser in connection with the transactions contemplated by the Transaction Documents.

 

6.17
Construction. The parties agree that each of them and/or their respective counsel has reviewed and had an opportunity to revise the
Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the
drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments hereto.

 

6.18
WAIVER OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES
EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY
AND EXPRESSLY WAIVES FOREVER TRIAL BY JURY.

 

[Remainder
of page intentionally left blank.]

 

    	33

     

    

 

In
Witness Whereof, the parties hereto have caused
this Securities Purchase Agreement to be duly executed by their respective authorized signatories as of the date first indicated above.

 

	 	PROVENTION BIO,
    INC.
	 	 	                
	 	 
	 	Name: 	 
	 	Title:	 
	 	 	 
	 	Address for Notice:
	 	 	 
	 	 	 
	 	Email:	 
	 	Attention:
	 	 	 
	 	With a copy to (which shall not constitute
    notice):

 

    	34

     

    

 

	 	PURCHASERS:
	 	 
	 	[Name
    of Purchaser]:
	 	 
	 	 
	 	 	                 
	 	By:	 
	 	Name:	 
	 	Title: 	 

 

	                          	Address: 	 
	 	 	 
	 	 	 

 

	                    	Shares
Beneficially Owned Prior to Initial Closing: 
	 

 

	                 	EIN:	 
	 	 	 
	 	Contact: 	 
	 	 	 
	 	Email: 	 

 

    	35

     

    

 

EXHIBIT
A

 

CLOSING
SCHEDULE

 

	Name	 	Shares of

                                                                                Common

                                                                                Stock to be Purchased
	 	Purchase Price

                                                                                for Common

                                                                                Stock
	 	Warrants to

                                                                                be Purchased
	 	Purchase

                                                                                Price for

                                                                                Warrants

	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 

 

    	36

     

    

 

EXHIBIT
B

 

    	37

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00346-of-00352.parquet"}]]